Health management devices and methods

Description

BACKGROUND

The detection of the level of analytes, such as glucose, lactate, oxygen, and the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes. Diabetics may need to monitor glucose levels to determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.

Accordingly, of interest are devices that allow a user to test for one or more analytes.

SUMMARY

In accordance with embodiments of the present disclosure, there is provided analyte monitoring methods and system for prospective or retrospective data analysis and processing including an in vivo analyte monitoring system comprising an analyte sensor and a module to collect analyte data from the sensor for use by a first user, a data management system to manipulate analyte data at a remote site, the analyte data transferred to the data management system from the in vivo system, where the system is configured for use by at least a second user, and further where there is provided a patient privacy system to limit or restrict data access by the type of users.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a block diagram of an embodiment of a data monitoring and management system according to the present disclosure;

FIG. 2 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system of FIG. 1;

FIG. 3 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system of FIG. 1;

FIG. 4 shows a schematic diagram of an embodiment of an analyte sensor according to the present disclosure;

FIGS. 5A-5B show a perspective view and a cross sectional view, respectively of another embodiment an analyte sensor;

FIGS. 6-10 illustrate exemplary blood glucose meters and test strips and using the same;

FIG. 11 illustrates in vitro data transfer to a health care provider (HCP) via Universal Serial Bus (USB) connection to a computing device such as a personal computer (PC) in one embodiment;

FIG. 12 illustrates prospective calibration of an assessor (AS) data, and unblinded assessor (AS) data in one embodiment;

FIG. 13 illustrates prospective calibration of the assessor (AS) data, unblinded data and associated analysis and an RF module in one embodiment;

FIG. 14 illustrates unblinded, retrospective data and associated analysis and a USB connection in one embodiment;

FIG. 15 illustrates unblinded, prospective data and associated analysis and a wireless adapter in one embodiment; and

FIG. 16 shows a table of exemplary embodiments and respective features in one embodiment.

DETAILED DESCRIPTION

Before the present disclosure is described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges as also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.

The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity.

Generally, embodiments of the present disclosure relate to methods and devices for detecting at least one analyte such as glucose in body fluid. Embodiments relate to the continuous and/or automatic in vivo monitoring of the level of one or more analytes using a continuous analyte monitoring system that includes an analyte sensor at least a portion of which is to be positioned beneath a skin surface of a user for a period of time and/or the discrete monitoring of one or more analytes using an in vitro blood glucose (“BG”) meter and an analyte test strip. Embodiments include combined or combinable devices, systems and methods and/or transferring data between an in vivo continuous system and a BG meter system.

Accordingly, embodiments include analyte monitoring devices and systems that include an analyte sensor—at least a portion of which is positionable beneath the skin of the user—for the in vivo detection, of an analyte, such as glucose, lactate, and the like, in a body fluid. Embodiments include wholly implantable analyte sensors and analyte sensors in which only a portion of the sensor is positioned under the skin and a portion of the sensor resides above the skin, e.g., for contact to a transmitter, receiver, transceiver, processor, etc. The sensor may be, for example, subcutaneously positionable in a patient for the continuous or periodic monitoring of a level of an analyte in a patient's interstitial fluid. For the purposes of this description, continuous monitoring and periodic monitoring will be used interchangeably, unless noted otherwise.

The sensor response may be correlated and/or converted to analyte levels in blood or other fluids. In certain embodiments, an analyte sensor may be positioned in contact with interstitial fluid to detect the level of glucose, which detected glucose may be used to infer the glucose level in the patient's bloodstream. Analyte sensors may be insertable into a vein, artery, or other portion of the body containing fluid. Analyte sensors that do not require bodily fluid contact are also contemplated. Embodiments of the analyte sensors may be configured for monitoring the level of the analyte over a time period which may range from minutes, hours, days, weeks, or longer.

Of interest are analyte sensors, such as glucose sensors, that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days of more, e.g., about three or more days, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month. Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time to, the rate of change of the analyte, etc. Predictive alarms may notify the user of a predicted analyte level that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.

FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system 100 in accordance with certain embodiments. Embodiments of the subject disclosure are further described primarily with respect to glucose monitoring devices and systems, and methods of glucose detection, for convenience only and such description is in no way intended to limit the scope of the disclosure. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes at the same time or at different times.

Analytes that may be monitored include, but are not limited to acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.

The analyte monitoring system 100 includes a sensor 101, a data processing unit or control unit 102 connectable to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103. In certain embodiments, the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104. The data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication. Further, the data processing unit 102 may include a transmitter or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104 and/or the data processing terminal 105 and/or optionally the secondary receiver unit 106.

Also shown in FIG. 1 is an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102. The secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104, as well as the data processing terminal 105. The secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in certain embodiments the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104. The secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device. A docking cradle may recharge a power supply.

Only one sensor 101, data processing unit 102 and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102, and/or more than one data processing terminal 105. Multiple sensors may be positioned in a patient for analyte monitoring at the same or different times. In certain embodiments, analyte information obtained by a first positioned sensor may be employed as a comparison to analyte information obtained by a second sensor. This may be useful to confirm or validate analyte information obtained from one or both of the sensors. Such redundancy may be useful if analyte information is contemplated in critical therapy-related decisions. In certain embodiments, a first sensor may be used to calibrate a second sensor.

The analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100. For example, unique IDs, communication channels, and the like, may be used.

In certain embodiments, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by the data processing unit 102. The data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously. The data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body. A mount (not shown) attachable to the user and mateable with the unit 102 may be used. For example, a mount may include an adhesive surface. The data processing unit 102 performs data processing functions, where such functions may include but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103. In one embodiment, the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.

In certain embodiments, the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103, and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, data bit recovery, etc., or any combination thereof.

In operation, the primary receiver unit 104 in certain embodiments is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102, based on, for example, an identification information of the data processing unit 102, and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101.

Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user.

The data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102. An infusion device may be an external device or an internal device (wholly implantable in a user).

In certain embodiments, the data processing terminal 105, which may include an insulin pump, may be configured to receive the analyte signals from the data processing unit 102, and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, the communication link 103 as well as one or more of the other communication interfaces shown in FIG. 1, may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements), while avoiding potential data collision and interference.

FIG. 2 shows a block diagram of an embodiment of a data processing unit of the data monitoring and detection system shown in FIG. 1. User input and/or interface components may be included or a data processing unit may be free of user input and/or interface components. In certain embodiments, one or more application-specific integrated circuits (ASIC) may be used to implement one or more functions or routines associated with the operations of the data processing unit (and/or receiver unit) using for example one or more state machines and buffers. Referring to the Figure, the data processing unit 102 in one embodiment includes an analog interface 201 configured to communicate with the sensor 101 (FIG. 1), a user input 202, and a temperature measurement section 203, each of which is operatively coupled to a processor 204 such as a central processing unit (CPU).

As can be seen in the embodiment of FIG. 2, the sensor 101 (FIG. 1) includes four contacts, three of which are electrodes—work electrode (W) 210, reference electrode (R) 212, and counter electrode (C) 213, each operatively coupled to the analog interface 201 of the data processing unit 102. This embodiment also shows optional guard contact (G) 211. Fewer or greater electrodes may be employed. For example, the counter and reference electrode functions may be served by a single counter/reference electrode, there may be more than one working electrode and/or reference electrode and/or counter electrode, and so on. The processor shown in FIG. 2 may be equipped with sufficient memory to store the data of interest (such as analyte data) for extended periods of time ranging from one to several samples to the number of samples obtained for an entire wear period of several days to weeks. In one aspect, the memory may be included as part of the processor 204. In another embodiment, a separate memory unit such as a memory chip, random access memory (RAM) or any other storage device for storing for subsequent retrieval data. The electronics of the on-skin sensor control unit and the sensor are operated using a power supply 207, e.g., a battery. Additionally, as can be seen from the Figure, clock 208 is provided to, among others, supply real time information to the processor 204. In one embodiment, a unidirectional input path is established from the sensor 101 (FIG. 1) and/or manufacturing and testing equipment to the analog interface 201 of the data processing unit 102, while a unidirectional output is established from the output of the RF transmitter 206 of the data processing unit 102 for transmission to the primary receiver unit 104. In this manner, a data path is shown in FIG. 2 between the aforementioned unidirectional input and output via a dedicated link 209 from the analog interface 201 to serial communication section 205, thereafter to the processor 204, and then to the RF transmitter 206. Also shown is a leak detection circuit 214 coupled to the guard contact (G) 211 and the processor 204 in the data processing unit 102. The leak detection circuit 214 in accordance with one embodiment of the present invention may be configured to detect leakage current in the sensor 101 to determine whether the measured sensor data are corrupt or whether the measured data from the sensor 101 is accurate.

FIG. 3 is a block diagram of an embodiment of a receiver/monitor unit such as the primary receiver unit 104 of the data monitoring and management system shown in FIG. 1. The primary receiver unit 104 includes one or more of: a blood glucose test strip interface 301, an RF receiver 302, an input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a processing and storage section 307. The primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the processing and storage unit 307. The receiver may include user input and/or interface components or may be free of user input and/or interface components.

In certain embodiments, the test strip interface 301 includes a glucose level testing portion to receive a blood (or other body fluid sample) glucose test or information related thereto. For example, the interface may include a test strip port to receive a glucose test strip. The device may determine the glucose level of the test strip, and optionally display (or otherwise notice) the glucose level on the output 310 of the primary receiver unit 104. Any suitable test strip may be employed, e.g., test strips that only require a very small amount (e.g., one microliter or less, e.g., 0.5 microliter or less, e.g., 0.1 microliter or less), of applied sample to the strip in order to obtain accurate glucose information, e.g. FreeStyle® blood glucose test strips from Abbott Diabetes Care Inc. Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc. For example, the information may be used to calibrate sensor 101, confirm results of the sensor 101 to increase the confidence thereof (e.g., in instances in which information obtained by sensor 101 is employed in therapy related decisions), and the like.

In further embodiments, the data processing unit 102 and/or the primary receiver unit 104 and/or the secondary receiver unit 106, and/or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly (or via a wire as shown in FIG. 12) over a communication link from, for example, a blood glucose meter. In further embodiments, a user manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in one or more of the data processing unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105.

Additional detailed description of embodiments of test strips, blood glucose (BG) meters and continuous monitoring systems and data management systems that may be employed are provided in but not limited to: U.S. Pat. Nos. 6,175,752; 6,560,471; 5,262,035; 6,881,551; 6,121,009; 7,167,818; 6,270,455; 6,161,095; 5,918,603; 6,144,837; 5,601,435; 5,822,715; 5,899,855; 6,071,391; 6,120,676; 6,143,164; 6,299,757; 6,338,790; 6,377,894; 6,600,997; 6,773,671; 6,514,460; 6,592,745; 5,628,890; 5,820,551; 6,736,957; 4,545,382; 4,711,245; 5,509,410; 6,540,891; 6,730,200; 6,764,581; 6,299,757; 6,461,496; 6,503,381; 6,591,125; 6,616,819; 6,618,934; 6,676,816; 6,749,740; 6,893,545; 6,942,518; 6,514,718; U.S. patent application Ser. No. 10/745,878 filed Dec. 26, 2003, now U.S. Pat. No. 7,811,231 entitled “Continuous Glucose Monitoring System and Methods of Use”, and elsewhere, the disclosures of each which are incorporated herein by reference for all purposes.

FIG. 4 schematically shows an embodiment of an analyte sensor in accordance with the present disclosure. This sensor embodiment includes electrodes 401, 402 and 403 on a base 404. Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like. Materials include but are not limited to aluminum, carbon (such as graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements.

The sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user. For example, the sensor 400 may include a portion positionable above a surface of the skin 410, and a portion positioned below the skin. In such embodiments, the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment of FIG. 4 shows three electrodes side-by-side on the same surface of base 404, other configurations are contemplated, e.g., fewer or greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc.

FIG. 5A shows a perspective view of an embodiment of an electrochemical analyte sensor 500 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of the skin 510, and a second portion (which in this embodiment may be characterized as a minor portion) that includes an insertion tip 530 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 520, in contact with the user's biofluid such as interstitial fluid. Contact portions of a working electrode 501, a reference electrode 502, and a counter electrode 503 are positioned on the portion of the sensor 500 situated above the skin surface 510. Working electrode 501, a reference electrode 502, and a counter electrode 503 are shown at the second section and particularly at the insertion tip 530. Traces may be provided from the electrode at the tip to the contact, as shown in FIG. 5A. It is to be understood that greater or fewer electrodes may be provided on a sensor. For example, a sensor may include more than one working electrode and/or the counter and reference electrodes may be a single counter/reference electrode, etc.

FIG. 5B shows a cross sectional view of a portion of the sensor 500 of FIG. 5A. The electrodes 510, 502 and 503, of the sensor 500 as well as the substrate and the dielectric layers are provided in a layered configuration or construction. For example, as shown in FIG. 5B, in one aspect, the sensor 500 (such as the sensor 101FIG. 1), includes a substrate layer 504, and a first conducting layer 501 such as carbon, gold, etc., disposed on at least a portion of the substrate layer 504, and which may provide the working electrode. Also shown disposed on at least a portion of the first conducting layer 501 is a sensing layer 508.

A first insulation layer such as a first dielectric layer 505 is disposed or layered on at least a portion of the first conducting layer 501, and further, a second conducting layer 509 may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) 505. As shown in FIG. 5B, the second conducting layer 509 may provide the reference electrode 502, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl), gold, etc.

A second insulation layer 506 such as a dielectric layer in one embodiment may be disposed or layered on at least a portion of the second conducting layer 509. Further, a third conducting layer 503 may provide the counter electrode 503. It may be disposed on at least a portion of the second insulation layer 506. Finally, a third insulation layer 507 may be disposed or layered on at least a portion of the third conducting layer 503. In this manner, the sensor 500 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer). The embodiment of FIGS. 5A and 5B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths.

In certain embodiments, some or all of the electrodes 501, 502, 503 may be provided on the same side of the substrate 504 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on the substrate 504. For example, co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in certain embodiments, one or more of the electrodes 501, 502, 503 may be disposed on opposing sides of the substrate 504. In such embodiments, contact pads may be on the same or different sides of the substrate. For example, an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate.

As noted above, analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer. Some analytes, such as oxygen, can be directly electro oxidized or electro reduced on a sensor, and more specifically at least on a working electrode of a sensor. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electro oxidation or electro reduction of the analyte. Catalysts may also be used for those analytes, such as oxygen, that can be directly electro oxidized or electro reduced on the working electrode. For these analytes, each working electrode includes a sensing layer (see for example sensing layer 508 of FIG. 5B) proximate to or on a surface of a working electrode. In many embodiments, a sensing layer is formed near or on only a small portion of at least a working electrode.

The sensing layer includes one or more components designed to facilitate the electrochemical oxidation or reduction of the analyte. The sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both.

A variety of different sensing layer configurations may be used. In certain embodiments, the sensing layer is deposited on the conductive material of a working electrode. The sensing layer may extend beyond the conductive material of the working electrode. In some cases, the sensing layer may also extend over other electrodes, e.g., over the counter electrode and/or reference electrode (or counter/reference is provided).

A sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte. For example, a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, such as glucose oxidase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electro oxidation of the glucose, lactate, or oxygen, respectively.

In other embodiments the sensing layer is not deposited directly on the working electrode. Instead, the sensing layer 508 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer. A separation layer may include one or more membranes or films or a physical distance. In addition to separating the working electrode from the sensing layer the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer.

In certain embodiments which include more than one working electrode, one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte. Thus, the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.

In certain embodiments, the sensing layer includes one or more electron transfer agents. Electron transfer agents that may be employed are electro reducible and electro oxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). The electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes such as ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc.

In certain embodiments, electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed. For example, electron transfer agents include but are not limited to a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode. The bond between the redox species and the polymer may be covalent, coordinative, or ionic. Although any organic, organometallic or inorganic redox species may be bound to a polymer and used as an electron transfer agent, in certain embodiments the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.

One type of polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition. An example of this type of mediator is poly(vinylferrocene). Another type of electron transfer agent contains an ionically-bound redox species. This type of mediator may include a charged polymer coupled to an oppositely charged redox species. Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation. Another example of an ionically-bound mediator is a positively charged polymer such as quaternized poly(4-vinyl pyridine) or poly(1-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide. In other embodiments, electron transfer agents include a redox species coordinatively bound to a polymer. For example, the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(1-vinyl imidazole) or poly(4-vinyl pyridine).

Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof. The electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof. One example of an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same. Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include but are not limited to 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, such as 4,4′-dimethoxy-2,2′-bipyridine. Derivatives of 1,10-phenanthroline for complexation with the osmium cation include but are not limited to 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline. Polymers for complexation with the osmium cation include but are not limited to polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”). Suitable copolymer substituents of poly(1-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole, e.g., electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).

Embodiments may employ electron transfer agents having a redox potential ranging from about −200 mV to about +200 mV versus the standard calomel electrode (SCE). The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.

The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.

In certain embodiments, a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent (which, as described above, may be polymeric. A second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode. Alternatively, a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.

Certain embodiments include a Wired Enzyme™ sensing layer (Abbott Diabetes Care Inc.) that works at a gentle oxidizing potential, e.g., a potential of about +40 mV. This sensing layer uses an osmium (Os)-based mediator designed for low potential operation and is stably anchored in a polymeric layer. Accordingly, in certain embodiments the sensing element is redox active component that includes (1) Osmium-based mediator molecules attached by stable (bidente) ligands anchored to a polymeric backbone, and (2) glucose oxidase enzyme molecules. These two constituents are crosslinked together.

A mass transport limiting layer (not shown), e.g., an analyte flux modulating layer, may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes. The mass transport limiting layers are useful in limiting the flux of an analyte to a working electrode in an electrochemical sensor so that the sensor is linearly responsive over a large range of analyte concentrations and is easily calibrated. Mass transport limiting layers may include polymers and may be biocompatible. A mass transport limiting layer may provide many functions, e.g., biocompatibility and/or interferent-eliminating, etc.

In certain embodiments, a mass transport limiting layer is a membrane composed of crosslinked polymers containing heterocyclic nitrogen groups, such as polymers of polyvinylpyridine and polyvinylimidazole. Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.

A membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution. The modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups. For example, a precursor polymer may be polyvinylpyridine or polyvinylimidazole. Optionally, hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest. Optional hydrophilic modifiers, such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.

A membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period. The crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like. Generally, the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors. A membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e. reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.

The description herein is directed primarily to electrochemical sensors for convenience only and is in no way intended to limit the scope of the disclosure. Other sensors and sensor systems are contemplated. Such include, but are not limited to, optical sensors, colorimetric sensors, and sensors that detect hydrogen peroxide to infer glucose levels, potentiometric sensors, coulometric sensors, or oxygen sensors.

For example, a hydrogen peroxide-detecting sensor may be constructed in which a sensing layer includes enzyme such as glucose oxides, glucose dehydrogenase, or the like, and is positioned proximate to the working electrode. The sending layer may be covered by a membrane that is selectively permeable to glucose. Once the glucose passes through the membrane, it is oxidized by the enzyme and reduced glucose oxidase can then be oxidized by reacting with molecular oxygen to produce hydrogen peroxide.

Certain embodiments include a hydrogen peroxide-detecting sensor constructed from a sensing layer prepared by crosslinking two components together, for example: (1) a redox compound such as a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials of about +200 mV vs. SCE, and (2) periodate oxidized horseradish peroxidase (HRP). Such a sensor functions in a reductive mode; the working electrode is controlled at a potential negative to that of the Os complex, resulting in mediated reduction of hydrogen peroxide through the HRP catalyst.

In another example, a potentiometric sensor can be constructed as follows. A glucose-sensing layer is constructed by crosslinking together (1) a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials from about −200 mV to +200 mV vs. SCE, and (2) glucose oxidase. This sensor can then be used in a potentiometric mode, by exposing the sensor to a glucose containing solution, under conditions of zero current flow, and allowing the ratio of reduced/oxidized Os to reach an equilibrium value. The reduced/oxidized Os ratio varies in a reproducible way with the glucose concentration, and will cause the electrode's potential to vary in a similar way.

A sensor may also include an active agent such as an anticlotting and/or antiglycolytic agent(s) disposed on at least a portion a sensor that is positioned in a user. An anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Examples of useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents. Embodiments may include an antiglycolytic agent or precursor thereof. Examples of antiglycolytic agents are glyceraldehyde, fluoride ion, and mannose.

Sensors may be configured to require no system calibration or no user calibration. For example, a sensor may be factory calibrated and may not require further calibration during the life of the sensor. In certain embodiments, calibration may be required, but may be done without user intervention, i.e., may be automatic. In those embodiments in which calibration by the user is required, the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, such as but not limited to glucose concentration and/or temperature and/or rate of change of glucose, etc.

Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care Inc.). For example, test strips that require less than about 1 nanoliter of sample may be used. In certain embodiments, a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained. Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combine with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.

Analyte systems may include an optional alarm system that, e.g., based on information from a processor, warns the patient of a potentially detrimental condition of the analyte. For example, if glucose is the analyte, an alarm system may warn a user of conditions such as hypoglycemia and/or hyperglycemia and/or impending hypoglycemia, and/or impending hyperglycemia. An alarm system may be triggered when analyte levels approach, reach or exceed a threshold value. An alarm system may also, or alternatively, be activated when the rate of change, or acceleration of the rate of change, in analyte level increase or decrease approaches, reaches or exceeds a threshold rate or acceleration. A system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc. Alarms may be, for example, auditory and/or visual. Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.

The subject disclosure also includes sensors used in sensor-based drug delivery systems. The system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors. Alternatively, the system may monitor the drug concentration to ensure that the drug remains within a desired therapeutic range. The drug delivery system may include one or more (e.g., two or more) sensors, a processing unit such as a transmitter, a receiver/display unit, and a drug administration system. In some cases, some or all components may be integrated in a single unit. A sensor-based drug delivery system may use data from the one or more sensors to provide necessary input for a control algorithm/mechanism to adjust the administration of drugs, e.g., automatically or semi-automatically. As an example, a glucose sensor may be used to control and adjust the administration of insulin from an external or implanted insulin pump.

In certain embodiments, a continuous glucose (“CG”) monitoring system (for example a FreeStyle Navigator® continuous glucose monitoring system or certain components thereof) may be used to assess diabetes and treatment options, e.g., assessed by a health care provider (“HCP”) device. Such an assessment may occur at initial phases of, or at the beginning of diagnosis or onset of, diabetic condition. A CG system may be provided to a user to monitor glucose levels for a period of time, e.g., about one day to about one month or more, e.g., about a few days to about a few weeks, e.g., about 1-2 weeks. The information gathered by the CG system may be reviewed retrospectively by an HCP, e.g., stored in an HCP device memory and communicated to (including transferred to) HCP, to assess the next steps of treating and/or monitoring the user's glucose levels to control diabetes. These CG systems may generally be referred to as “assessor” (“AS”) systems. Generally, a CG system is an in vivo system, e.g., that a user may borrow/rent/otherwise obtain whenever they are collecting glucose data.

In certain embodiments, an HCP may use AS system data obtained from a user to assess whether the user would benefit from using an in vitro meter (test strip and meter, including an integrated glucose monitoring system). The HCP may then prescribe such a system for the user. Of course, an HCP may determine that the user continue to use an in vivo system or that no additional glucose monitoring is required. In many embodiments, an HCP may determine (and prescribe) a short assay time/small sample size in vitro system, and a user may monitor their glucose levels using such a system. Accordingly, after using an AS system to monitor glucose levels for a period of time, an HCP may, after reviewing the AS data obtained during this time, recommend that the user to continue to monitor glucose levels using an in vitro system. Typically (though not always) the user may use the in vitro system as the primary and sole source of glucose monitoring, i.e., the AS system need not be used by the user any longer, or may be used periodically.

In certain embodiments, a given AS system may be used to monitor glucose levels of a first person, an HCP may review the data therefrom, and the AS system may then be used by at least a second person (excluding the analyte sensor).

As noted above, an HCP may recommend (and prescribe) an in vitro system for a user if AS data reviewed by the HCP after being used for a period of time indicates that such a system would be beneficial for the user/patient.

Embodiments include devices which allow diabetics or users evaluating whether they have diabetes to measure the blood (or other bodily fluid) glucose levels, e.g., hand-held electronic meters (blood glucose meters), e.g., such as Freestyle® or Precision® blood glucose monitoring systems available from Abbott Diabetes Care Inc., of Alameda, Calif. which receives blood samples via enzyme-based test strips. Typically, a user inserts a test strip into a meter and lances a finger or alternate body site to obtain a blood sample. The drawn sample is applied to the test strip and the meter reads the strip and determines analyte concentration, which is then conveyed to the user. For example, a blood glucose meter may convert a current generated by the enzymatic reaction in the test strip to a corresponding blood glucose value which is displayed or otherwise provided to the patient to show the level of glucose at the time of testing. Such periodic discrete glucose testing helps diabetic patients to take any necessary corrective actions to better manage diabetic conditions.

Test strips for use with such in vitro systems may be adapted to measure the concentration of an analyte in any volume of sample, including but not limited to small volumes of sample, e.g., about 1 microliter or less sample, for example about 0.5 microliters or less, for example about 0.3 microliters or less, for example about 0.1 microliters or less. In some embodiments, the volume of sample may be as low as about 0.05 microliters or as low as about 0.03 microliters. Strips may be configured so that an accurate analyte measurement may be obtained using a volume of sample that wholly or partially fills a sample chamber of a strip. In certain embodiments, a test may only start when sufficient sample has been applied to a strip, e.g., as detected by a detector such as an electrode. An in vitro system may be programmed to allow re-application of additional sample if insufficient sample is firstly applied, e.g., the time to reapply sample may range from about 10 seconds to about 2 minutes, e.g., from about 30 seconds to about 60 seconds.

Strips may be side fill, front fill, top fill or corner fill, or any combination thereof. Test strips may be calibration-free, e.g., minimal input (if any) is required of a user to calibrate. In certain embodiments, no calibration test strips may be employed. In such embodiments, the user need not take any action for calibration, i.e., calibration is invisible to a user.

As noted above, strips are used with meters. In certain embodiments, meters may be integrated meters, i.e., a device which has at least one strip and at least a second element, such as a meter and/or a skin piercing element such as a lancet or the like, in the device. In some embodiments, a strip may be integrated with both a meter and a lancet, e.g., in a single housing. Having multiple elements together in one device reduces the number of devices needed to obtain an analyte level and facilitates the sampling process. For example, embodiments may include a housing that includes one or more analyte test strips, a skin piercing element and a processor for determining the concentration of an analyte in a sample applied to the strip. A plurality of strips may be retained in a magazine in the housing interior and, upon actuation by a user, a single strip may be dispensed from the magazine so that at least a portion extends out of the housing for use.

Test strips may be short test time test strips. For example, test times may range from about 1 second to about 20 seconds, e.g., from about 3 seconds to about 10 seconds, e.g., from about 3 seconds to about 7 seconds, e.g., about 5 seconds or about 3 seconds.

Exemplary meters and test strips and using the same are shown in FIGS. 6-10.

In certain embodiments, the glucose levels obtained by the AS system may not be displayed or otherwise communicated to a user in real time, i.e., the user of the system will be blinded to the data obtained—at least in real time. Stated otherwise, no glucose results are shown on the AS system. The AS data will thus be retrospective providing blind data, and will include a device (wired or wireless) so that an HCP device may download retrospective continuous glucose monitoring system data from the AS system for review and analysis. In certain embodiments, the AS system will not be calibrated in real time, e.g., will not include (or will not include a functional or the strip port will be blocked) strip port to accept a calibration test strip. An in vitro system may be used concurrently with the system, and the data obtained by the in vitro system reviewed and used in the review and/or processing of AS data. For example, the in vitro data may be used to retrospectively calibrate the CG data, e.g., at a remote site such as an HCP site, and as shown, for example, in FIG. 11.

Referring to FIG. 11, in one aspect, a user wears and uses an AS system that includes an in vivo analyte sensor (not shown) coupled to an AS data processing unit (transmitter) worn (in this embodiment) on the user's arm, and an AS receiver unit to receive information from the AS data processing unit (wired or wirelessly). A blood glucose (“BG”) or in vitro meter (used interchangeably) is also used and is configured to transfer data to a remote site such as shown here an HCP PC terminal (either wirelessly or otherwise). Also included is a data management system (“DMS”). There is no data transfer connection between the in vitro meter and the AS system, data transfer exists between the AS system and a DMS, such as a PC-based DMS.

In the particular embodiment of FIG. 11, in vitro data is transferred to the HCP PC terminal via USB connection. The PC terminal may be at the user's location, at which the data may then be accessed by the HCP (e.g., via a network connection, server connection or otherwise), or downloaded to a computing device at the remote location. Once the HCP collects AS data (which may be transferred to the HCP as raw data or may be processed at least in certain respects), the data may be reviewed and/or further processed. For example, the AS data may be calibrated using the collected in vitro data. The calibrated AS data may then be reviewed and/or processed further. For example, reports may be generated. A data management system may be employed, e.g., such as the CoPilot™ data management system available from Abbott Diabetes Care Inc., or analogous system. The HCP PC terminal may generate and review reports produced using the AS data.

Accordingly, in certain embodiments an HCP attaches the AS processing unit with transmitter to the user at the HCP office and provides a reusable receiver unit to the user. The user may wear and collect data with the AS receiver and transmitter for about one or more days, e.g., about 2-30 days, e.g., about 3-7 days, e.g., about 5-7 days. The user performs BG tests on their in vitro meter at appropriate times, e.g., at 1, 2, 10, 24 and/or 72 hours after AS sensor insertion in certain embodiments. The user brings the AS receiver unit and in vitro meter to the HCP office and the HCP connects the in vitro meter via a USB cable (or otherwise including wirelessly) to a computing device such as the PC terminal and downloads the in vitro data from the meter's memory. The AS receiver wirelessly (or otherwise) transmits data to the PC. The HCP may view the AS and/or BG information using a DMS loaded and running on the HCP PC terminal.

In one aspect, the data obtained by the in vitro meter includes a time stamp based, for example, from an internal clock. The in vitro meter in one aspect may be synchronized with the clock of the PC terminal so that when the time stamped blood glucose values are received from the in vitro meter, the time of day information associated with each blood glucose test and the resulting blood glucose values are time synchronized with the corresponding analyte data in the PC terminal for further processing and analysis. In this manner, improved accuracy may be obtained. Further, the transmitted blood glucose values from the in vitro meter may also be associated with the unique identifier of the in vitro meter. In this manner, each blood glucose value derived or obtained from the in vitro meter will identify the corresponding in vitro meter based on its unique identifier.

In this manner, in one aspect, the user may be provided with limited or no real time data from the AS receiver during the time the glucose data is collected from the user. As such, user behavior or health care or treatment based decisions are limited or avoided by not allowing the user to view the on-going continuous glucose level monitored by the AS sensor and collected by the AS system. In one aspect, the AS system may be configured to provide limited output information to the user during the data collection modes, such as an indication that the AS system is functioning properly (for example, with periodic audible alerts, visual displays indicating system integrity, and the like). Other information may likewise be displayed or output on the AS receiver to the user such as, for example, the time of day information, the duration of the data collection elapsed, and so on.

Certain embodiments include prospective calibration of AS data, and unblinded AS data. An exemplary embodiment of such a system is shown in FIG. 12. This embodiment includes an AS data processing unit that includes a transmitter worn and used by a user, an AS receiving unit, an in vitro meter capable of transferring data to the AS system, (herein shown using a wired connection, but wireless may also be used), and a DMS. Accordingly, in this embodiment, glucose results of the AS system are communicated to the user in real-time, e.g., audibly and/or visually such as on a display. There is unidirectional transfer of data from the in vitro blood glucose meter to the AS receiver, e.g., using a USB cable or the like. In certain embodiments, the transfer of data may be bidirectional so the BG meter could (for example) display the most recent CG data. This would greatly enhance the value of the BG meter (to be able to display glucose data without the pain of drawing the blood), and more generally the BG meter may be used as a display unit for medical data besides just BG. For example, this may be included in a Data Logger embodiment. The embodiment of FIG. 12 can be configured to show or not show (“blind”) CG data since it uses prospective data.

Accordingly, in certain embodiments an HCP attaches the AS processing unit with transmitter to a user at the HCP office and provides a loaner or reusable AS receiver. The user may wear and collect data with the AS receiver and transmitter for about one or more days, e.g., about 2-30 days, e.g., about 3-7 days, e.g., about 5-7 days. The user performs BG tests on their in vitro meter at appropriate times, e.g., at 10, 24 and 72 hours after AS sensor insertion in certain embodiments. When the user performs a BG test on their in vitro meter, the user couples (wired or wirelessly) the meter to the AS receiver. The AS receiver may be calibrated using this transferred BG data. The user brings the AS receiver and in vitro meter to the HCP office. The AS receiver wirelessly (or otherwise) transmits data to the PC. The HCP may view the AS and/or BG information using a DMS.

Certain embodiments include prospective calibration of AS data, unblinded data and an RF module. An exemplary embodiment of such a system is shown in FIG. 13. This embodiment includes an AS data processing unit that includes a transmitter worn and used by a user, an AS receiving unit, an in vitro meter capable of transferring data to the AS system, herein shown using a wired connection, (but wireless may also be used), an RF module, and a DMS. Accordingly, in this embodiment glucose results of the AS system are communicated to the user in real-time, e.g., audibly and/or visually such as on a display. As shown, there is unidirectional transfer of data from the in vitro blood glucose meter to the AS receiver, e.g., using RF and a wireless adaptor coupled to the in vitro meter. However, there may be bidirectional transfer of data that permits the in vitro meter to display AS data (i.e., the in vitro meter including functionality to output the continuous analyte sensor data).

Accordingly, in certain embodiments an HCP attaches the AS processing unit with transmitter to a user at the HCP office and provides a loaner or reusable AS receiver. The user may wear and collect data with the AS receiver and transmitter for about one or more days, e.g., about 2-30 days, e.g., about 3-7 days, e.g., about 5-7 days. The user performs BG tests on their in vitro meter at appropriate times, e.g., at 10, 24 and 72 hours after AS sensor insertion in certain embodiments. When the user performs a BG test on their in vitro meter, the wireless adapter will have to be coupled to the meter and the BG test data may be wirelessly sent to the AS receiver. The collected data in the AS receiver may be calibrated using this transferred BG data. The user brings the AS receiver and in vitro meter to the HCP office. The AS receiver wirelessly (or otherwise) transmits data to the PC. The HCP may view the AS data and/or BG information using a DMS.

Certain embodiments include unblinded, retrospective data and a USB cable. An exemplary embodiment of such a system is shown in FIG. 14. This embodiment includes a Data Logger, a USB cable, a serial cable to Data Logger and an enhanced BG meter having continuous glucose monitoring functionalities. Accordingly, in this embodiment continuous glucose monitoring capabilities are accorded with the in vitro meter, which includes a mini usb port. A user wears the Data Logger and may view the retrospective data obtained by the Data Logger on the in vitro meter. There is unidirectional transfer (wired or wireless) of data from Data Logger to the BG meter—or may be bidirectional to allow calibration of the CG data with BG data as well as to display CG data on the BG meter.

Accordingly, in certain embodiments an HCP attaches an in vivo sensor and Data Logger to a user at the HCP office. The user may wear and collect data with the Data Logger (for example, provided in the AS transmitter coupled to the in vivo sensor) for about one or more days, e.g., about 2-30 days, e.g., about 3-7 days, e.g., about 5-7 days. The user connects the USB cable from the Data Logger to the BG meter to download results. The user brings the BG meter to the HCP site and transits data, e.g., via usb cable, from the BG meter to the HCP PC or computer terminal. The HCP may view the Data Logger and/or BG information using a DMS.

Certain embodiments include unblinded, prospective data and a wireless adapter. An exemplary embodiment of such a system is shown in FIG. 15. This embodiment includes a BG meter, an RF module and a Data Logger. The BG meter is an enhanced BG meter having continuous glucose monitoring functionalities and a USB port. A user wears a Data Logger and can view prospective data of the Data Logger on the BG meter. There is bidirectional transfer (wired or wireless) of data from Data Logger to the BG meter.

Accordingly, in certain embodiments an HCP attaches an in vivo sensor and Data Logger to a user at the HCP office. The user may wear and collect data with the Data Logger and transmitter for about one or more days, e.g., about 2-30 days, e.g., about 3-7 days, e.g., about 5-7 days. The user connects the wireless adapter to the BG meter to download results. The user brings the BG meter to the HCP site and transits data, e.g., via the wireless adapter, from the BG meter to the HCP pc. HCP may view the Data Logger and/or BG information using a DMS.

In certain embodiments, an AS receiver unit may be embedded in a BG meter. That is, the BG meter may be configured to directly communicate with the AS transmitter and to receive/store data from the AS transmitter and collect the monitored glucose levels from the in vivo sensor.

While in the embodiments described above, specific implementation of data communication including wired or cabled and wireless, and data processing is described, within the scope of the present disclosure, other data communication techniques may be used including wired over a cable connection and/or wireless over a communication link such as RF communication link, infrared communication link, Bluetooth® communication link, and the like, as well as networked data communication over data networks such as, but not limited to local area network, wide area network, metropolitan area network and the like, using data protocols such as, but not limited to TCP/IP, Internet Protocol version 4 (IPv4), Internet Protocol version 6 (IPv6), wireless application protocol (WAP), and the like.

FIG. 16 shows a table of exemplary embodiments and respective features that may be included. Any feature may be combined with any other embodiment, and/or features may be removed and/or added from/to any embodiment.

In one aspect, a data management system may generate a variety of reports, including 3 and/or 5 and/or 7 day reports of AS data and/or BG data. In certain embodiments, all or substantially all data processing is performed by the DMS, e.g., calibration of AS data, data analysis, mining, aggregation, filtering, and other suitable or desirable data processing functions including for example, therapy based analysis.

Data may be encrypted/decrypted and/or password protected for communication or transfer over one or more data networks or using one or more data communication protocol described above, for example. Additionally, data integrity and validation may be performed, for example, for detecting and/or correcting errors in the transmitted data using, for example, but not limited to, cyclic redundancy code (CRC), Manchester encoding/decoding, and the like. The AS system may include a unique identifier which may be known at the remote site (e.g., by the HCP system), to ensure data is correctly attributed to the correct user at the HCP site. Embodiments include various patient privacy protections, e.g., in accordance with The Health Insurance Portability and Accountability Act (HIPAA). In other words, systems herein may be HIPAA compliant.

In certain embodiments, data may be directly, e.g., automatically, transferred into a user's medical records (electronic record), billing data, etc. e.g., from the DMS. Embodiments include those capable to complete seamless downloads to electronic medical records systems. In certain embodiments, a reimbursement code may be automatically determined by the system for the HCP, e.g., Medical and/or Medicaid and/or various state codes. Determining such codes may be time consuming and complex. An analyte system that performs this task would be a great benefit to HCPs and users. For example, a reimbursement code may be determined by a system such as a DMS and displayed audibly and/or visually on a user interface display. The code may be automatically entered into a patient's records and/or reimbursement files and “paperwork”. Embodiments include those capable to complete seamless identification of reimbursement code(s) and/or download such to one or more compatible electronic systems. Accordingly, certain embodiments are self-documenting.

As noted above, embodiments are configured to ensure patient privacy, e.g., are HIPAA compliant. For example, as described above some embodiments include components that may be used by more than one individual. Patient data may be patient identification (ID) identified and all patient data from a first user may be automatically deleted from the system or one or more system components when the system is configured for a second user, e.g., by an HCP. For example, an AS data processing unit and/or receiving unit may require an initialization procedure for each use or user, e.g., performed by an HCP or the user, which requires entry of a password or other unique patient identifier. Patient specific data may be automatically deleted or the initializer may be prompted to delete during initialization of the CG system. Likewise, patient specific data may be scrambled, encrypted, or otherwise rendered indiscernible. Patient data may be deleted based on a time schedule in certain embodiments.

The AS systems and methods may be applicable for Type I and Type II diabetics, newly diagnosed diabetics, patients experiencing diabetic condition, post surgery glycemic control and the like. The AS systems and methods may be used in conjunction with multiple users or patients, for data analysis or therapy management.

The components of the embodiments herein may be combined in a single housing or may be separate. Further, embodiments may be re-usable, such that, they may be used by a plurality of users. In certain embodiments, DMS may be a PC based application, e.g., a Windows application.

Embodiments may include a module that (1) supports bidirectional or unidirectional RF (or infrared “IR”, or Bluetooth®) communication between the module and a CG transmitter unit and/or Data Logger, and/or (2) communicates to a BG meter via a wired connection (such as a cable or set of contacts), (3) communicates to a data processing terminal such as a PC (e.g., unit 105) via RF, IR or a wired cable, and/or contains a microprocessor (CPU) to handle all of the communication and data processing tasks.

For example, a module may serve as a communications hub between a BG meter, a PC and a CG transmitter or Data Logger, thereby enabling CG-BG calibration, the display of CG data on the BG meter, data transfer to a DMS, and data collection for retrospective or prospective analysis. By having this capability, the overall system is very cost effective and easy to use since the display and BG capabilities of the BG meter aren't duplicated elsewhere in the system, and the overall system would have complete CG functionality without adding any significant extra cost to the base HCP meter.

Accordingly, an analyte monitoring device such as an assessor in one embodiment may include a data collection module for receiving and storing analyte data over a predetermined time period from a subject, a user interface unit coupled to the data collection module for providing one or more indication related to the analyte data, a control unit coupled to the data collection module and the user interface unit to control, at least in part the operation of the data collection module and the user interface unit, and a communication module coupled to the control unit for communicating one or more signals associated with the analyte data to a remote location, where the user interface unit is configured to operate in a prospective analysis mode including substantially real time output of the analyte level received by the data collection module, and a retrospective analysis mode including limited output of information to the subject during the predetermined time period, and further where the communication module is configured to communicate with the remote location after the analyte data is received and stored in the data collection module over the predetermined time period.

The device may include a strip port operatively coupled to the control unit for receiving a blood glucose test strip.

The communication module in one embodiment may be configured to communicate with the remote location using one or more of a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth® communication protocol, or an 802.11x communication protocol.

The user interface unit may be configured to not display any information related to the received analyte data in the retrospective analyte mode.

In one aspect, the limited output of information during the retrospective analysis mode may include output to the user interface unit of one or more of the analyte monitoring device operational status information, a time of day information, a user profile information, or the elapsed duration of the predetermined time period.

The data collection module may include one or more of a data storage device or a memory device, where the memory device may be a random access memory.

In another aspect, the data collection module may be configured to delete the stored analyte data after transferring the analyte data to the remote location.

The remote location may include a data processing terminal such as an HCP PC terminal.

In a further aspect, during the prospective analysis mode, the user interface unit may be configured to visually output real time information related to the received analyte data of the subject, where the visual output may include one or more of a graphical output, a numerical output, or a text output.

The stored analyte data in the data collection module may be uncalibrated.

The communicated one or more signals associated with the analyte data to the remote location may include uncalibrated analyte data.

In a further aspect, the communication module may be configured to receive one or more calibration information, where the calibration information may include blood glucose data.

Also, the control unit may be configured to calibrate the received and stored analyte data based on the received calibration information to generate calibrated analyte data, where the data collection module may be configured to store the calibrated analyte data.

Further, the communication module may be configured to transmit the calibrated analyte data to the remote location.

A method in another embodiment may include storing analyte data over a predetermined time period received from a subject, providing one or more indication related to the received analyte data on a user interface unit, including operating the user interface unit in a prospective analysis mode including substantially real time output of the analyte level received by the data collection module, and a retrospective analysis mode including limited output of information to the subject during the predetermined time period, and communicating one or more signals associated with the analyte data to a remote location after the analyte data is received and stored over the predetermined time period.

The method in another aspect may include receiving a blood glucose test data.

The method may also include communicating with the remote location using one or more of a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth® communication protocol, or an 802.11x communication protocol.

The method may include not displaying any information related to the received analyte data in the retrospective analyte mode.

The limited output of information during the retrospective analysis mode may include outputting one or more of an operational status information, a time of day information, a user profile information, or the elapsed duration of the predetermined time period.

In still another aspect, the method may include deleting the stored analyte data after transferring the analyte data to the remote location.

Also, during the prospective analysis mode, the method may include visually outputting real time information related to the received analyte data of the subject, where the visual output may include one or more of a graphical output, a numerical output, or a text output.

In another aspect, the stored analyte data may be uncalibrated.

The method may include transmitting uncalibrated analyte data to the remote location.

Further, the method in yet another aspect may include receiving one or more calibration information, where the calibration information may include blood glucose data.

In yet a further aspect, the method may include calibrating the received and stored analyte data based on the received calibration information to generate calibrated analyte data.

The method may also include storing the calibrated analyte data.

Additionally, the method may include transmitting the calibrated analyte data to the remote location.

In yet a further aspect, the in vitro blood glucose meter may be configured to output or otherwise display the analyte sensor data, where the blood glucose meter includes a memory unit such as random access memory or other similar storage unit to store the analyte sensor data (which may be a one minute analyte related data over a time period of one to seven days, for example). Other time periods for the storage of analyte related data may be contemplated including, for example, longer than seven days, and further, the each analyte related data may be a five minute data or 10 minute data, for example.

In another aspect, the clocks in the in vitro blood glucose meter and the receiver unit (FIG. 1) may be time synchronized initially or during use, or periodically, such that the blood glucose value obtained by the in vitro blood glucose meter has a time corresponding analyte sensor data from the analyte sensor 101 (FIG. 1).

Various other modifications and alterations in the structure and method of operation of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with specific embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims

1. A healthcare provider receiving device for glucose data obtained from a plurality of patients of a healthcare provider, comprising: a wireless communication component configured to communicate with each of a plurality of glucose monitoring systems, each of the plurality of glucose monitoring systems comprising one or more data processing units coupled to a corresponding transcutaneous glucose sensor, each corresponding transcutaneous glucose sensor configured to be positioned at least in part in contact with a fluid under a skin layer of a patient of the plurality of patients of the healthcare provider, each one or more data processing units configured to generate glucose data of a corresponding patient of the plurality of patients from the corresponding transcutaneous glucose sensor, each one or more data processing units having a memory configured to store corresponding glucose data generated during an entire wear period of several days to weeks;a USB port; andone or more processors configured to, for each patient: cause an operational status of the corresponding glucose monitoring system to be displayed at the healthcare provider receiving device during the wear period,obtain the stored glucose data of the patient from the corresponding one or more data processing units, wherein the receiver does not allow the patient to view the stored glucose data such that the patient is blinded during the entire wear period, andtransmit the glucose data of the patient to a healthcare provider computing device using the USB port.
2. The device of claim 1, wherein the glucose data transmitted to the healthcare provider computing device comprises calibrated glucose data.
3. The device of claim 1, wherein the one or more processors are further configured to transmit a unique identifier to the healthcare provider computing device, wherein the unique identifier is used by a remote server associate the glucose data with the corresponding patient of the plurality of patients.
4. The device of claim 3, wherein the unique identifier comprises identification information of the one or more data processing units.
5. The device of claim 4, wherein the unique identifier is encrypted.
6. The device of claim 1, wherein the one or more processors are configured to check for errors in the transmitted glucose data using cyclic redundancy checks.
7. The device of claim 1, wherein the operational status comprises an indication of system integrity.
8. The device of claim 1, wherein the operational status comprises a duration of data collection.
9. The device of claim 1, wherein the wireless communication component is configured to communicate with each of the plurality of glucose monitoring systems by a Bluetooth protocol.
10. A healthcare provider monitoring system for glucose data obtained from a plurality of patients of a healthcare provider, comprising: a plurality of glucose monitoring systems, each of the plurality of glucose monitoring systems comprising: a transcutaneous glucose sensor configured to be positioned at least in part in contact with a fluid under a skin layer of a patient of the plurality of patients of the healthcare provider, andone or more data processing units coupled to the transcutaneous glucose sensor and configured to generate glucose data from the transcutaneous glucose sensor, the one or more data processing units having a memory configured to store the glucose data generated during an entire wear period of several days to weeks, anda healthcare provider receiving device comprising: a wireless communication component configured to communicate with each of the plurality of glucose monitoring systems,a USB port, andone or more processors configured to, for each patient: cause an operational status of the corresponding glucose monitoring system to be displayed at the healthcare receiving device during the wear period,obtain the stored glucose data of the patient from the corresponding one or more data processing units, wherein the receiver does not allow the patient to view the stored glucose data such that the patient is blinded during the entire wear period, andtransmit the glucose data of the patient to a healthcare provider computing device using the USB port.
11. The system of claim 10, wherein the stored glucose data comprises calibrated glucose data.
12. The system of claim 10, wherein the stored glucose data comprises uncalibrated glucose data, and the uncalibrated glucose data is transformed into calibrated glucose data using the one or more processors with no user intervention.
13. The system of claim 10, wherein the stored glucose data comprises uncalibrated glucose data, and the uncalibrated glucose data is transformed into calibrated glucose data using the one or more processors without using an in vitro glucose test strip.
14. The system of claim 10, wherein the glucose data transmitted to the healthcare provider computing device comprises calibrated glucose data.
15. The system of claim 10, further comprising a remote server configured to receive the glucose data from the healthcare provider computing device via a network connection.
16. The system of claim 15, wherein the remote server is configured to provide access to the glucose data or a report of the glucose data via a network connection.
17. The system of claim 15, wherein the remote server is further configured to receive a patient identifier to associate the glucose data with the corresponding patient.
18. The system of claim 17, wherein the patient identifier is encrypted.
19. The system of claim 15, wherein the one or more processors and/or the remote server are configured to check for errors in the transmitted glucose data using cyclic redundancy checks.
20. The system of claim 10, wherein the one or more data processing units comprise an application specific integrated circuit configured to implement one or more routines associated with the generation and/or storage and/or calibration and/or Bluetooth communication of the glucose data.
21. The system of claim 10, wherein the operational status comprises an indication of system integrity.
22. The system of claim 10, wherein the operational status comprises a duration of data collection.
23. The system of claim 10, wherein the one or more data processing units comprise a Bluetooth transmitter.

RELATED APPLICATIONS

The present application is a continuation of Ser. No. 17/019,122 filed Sep. 11, 2020, which is a continuation of U.S. patent application Ser. No. 16/032,017 filed Jul. 10, 2018, which is a continuation of U.S. patent application Ser. No. 14/094,719 filed Dec. 2, 2013, which is a continuation of U.S. patent application Ser. No. 12/143,731 filed Jun. 20, 2008, now U.S. Pat. No. 8,597,188, which claims priority to U.S. Provisional Application No. 60/945,579 filed Jun. 21, 2007, entitled “Health Management Devices and Methods” and assigned to the assignee of the present application, Abbott Diabetes Care Inc., the disclosures of each of which are incorporated by reference for all purposes.

US Referenced Citations (1111)

Number	Name	Date	Kind
3581062	Aston	May 1971	A
3926760	Allen et al.	Dec 1975	A
3949388	Fuller	Apr 1976	A
4036749	Anderson	Jul 1977	A
4055175	Clemens et al.	Oct 1977	A
4129128	McFarlane	Dec 1978	A
4245634	Albisser et al.	Jan 1981	A
4327725	Cortese et al.	May 1982	A
4344438	Schultz	Aug 1982	A
4349728	Phillips et al.	Sep 1982	A
4373527	Fischell	Feb 1983	A
4392849	Petre et al.	Jul 1983	A
4425920	Bourland et al.	Jan 1984	A
4431004	Bessman et al.	Feb 1984	A
4478976	Goertz et al.	Oct 1984	A
4494950	Fischell	Jan 1985	A
4509531	Ward	Apr 1985	A
4527240	Kvitash	Jul 1985	A
4538616	Rogoff	Sep 1985	A
4545382	Higgins et al.	Oct 1985	A
4619793	Lee	Oct 1986	A
4671288	Gough	Jun 1987	A
4684245	Goldring	Aug 1987	A
4703324	White	Oct 1987	A
4703756	Gough et al.	Nov 1987	A
4711245	Higgins et al.	Dec 1987	A
4731726	Allen, II	Mar 1988	A
4749985	Corsberg	Jun 1988	A
4757022	Shults et al.	Jul 1988	A
4777953	Ash et al.	Oct 1988	A
4779618	Mund et al.	Oct 1988	A
4818994	Orth et al.	Apr 1989	A
4854322	Ash et al.	Aug 1989	A
4871351	Feingold	Oct 1989	A
4890620	Gough	Jan 1990	A
4925268	Iyer et al.	May 1990	A
4953552	DeMarzo	Sep 1990	A
4986271	Wilkins	Jan 1991	A
4995402	Smith et al.	Feb 1991	A
5000180	Kuypers et al.	Mar 1991	A
5002054	Ash et al.	Mar 1991	A
5019974	Beckers	May 1991	A
5050612	Matsumura	Sep 1991	A
5051688	Murase et al.	Sep 1991	A
5055171	Peck	Oct 1991	A
5068536	Rosenthal	Nov 1991	A
5082550	Rishpon et al.	Jan 1992	A
5106365	Hernandez	Apr 1992	A
5122925	Inpyn	Jun 1992	A
5124661	Zellin et al.	Jun 1992	A
5135004	Adams et al.	Aug 1992	A
5165407	Wilson et al.	Nov 1992	A
5245314	Kah et al.	Sep 1993	A
5246867	Lakowicz et al.	Sep 1993	A
5262035	Gregg et al.	Nov 1993	A
5262305	Heller et al.	Nov 1993	A
5264104	Gregg et al.	Nov 1993	A
5264105	Gregg et al.	Nov 1993	A
5279294	Anderson et al.	Jan 1994	A
5285792	Sjoquist et al.	Feb 1994	A
5289497	Jackobson et al.	Feb 1994	A
5293877	O'Hara et al.	Mar 1994	A
5299571	Mastrototaro	Apr 1994	A
5305008	Turner et al.	Apr 1994	A
5320715	Berg	Jun 1994	A
5320725	Gregg et al.	Jun 1994	A
5322063	Allen et al.	Jun 1994	A
5333615	Craelius et al.	Aug 1994	A
5340722	Wolfbeis et al.	Aug 1994	A
5342408	deCoriolis et al.	Aug 1994	A
5342789	Chick et al.	Aug 1994	A
5356786	Heller et al.	Oct 1994	A
5360404	Novacek et al.	Nov 1994	A
5372133	Hogen Esch	Dec 1994	A
5372427	Padovani et al.	Dec 1994	A
5379238	Stark	Jan 1995	A
5390671	Lord et al.	Feb 1995	A
5391250	Cheney, II et al.	Feb 1995	A
5400794	Gorman	Mar 1995	A
5408999	Singh et al.	Apr 1995	A
5410326	Goldstein	Apr 1995	A
5411647	Johnson et al.	May 1995	A
5425868	Pedersen	Jun 1995	A
5431160	Wilkins	Jul 1995	A
5431921	Thombre	Jul 1995	A
5462051	Oka et al.	Oct 1995	A
5462645	Albery et al.	Oct 1995	A
5472317	Field et al.	Dec 1995	A
5489414	Schreiber et al.	Feb 1996	A
5497772	Schulman et al.	Mar 1996	A
5499243	Hall	Mar 1996	A
5507288	Bocker et al.	Apr 1996	A
5509410	Hill et al.	Apr 1996	A
5514718	Lewis et al.	May 1996	A
5531878	Vadgama et al.	Jul 1996	A
5532686	Urbas et al.	Jul 1996	A
5543326	Heller et al.	Aug 1996	A
5544196	Tiedmann, Jr. et al.	Aug 1996	A
5558638	Evers et al.	Sep 1996	A
5568806	Cheney, II et al.	Oct 1996	A
5569186	Lord et al.	Oct 1996	A
5581206	Chevallier et al.	Dec 1996	A
5582184	Erickson et al.	Dec 1996	A
5586553	Halili et al.	Dec 1996	A
5593852	Heller et al.	Jan 1997	A
5600301	Robinson, III	Feb 1997	A
5601435	Quy	Feb 1997	A
5609575	Larson et al.	Mar 1997	A
5623933	Amano et al.	Apr 1997	A
5628310	Rao et al.	May 1997	A
5628890	Carter et al.	May 1997	A
5634468	Platt et al.	Jun 1997	A
5653239	Pompei et al.	Aug 1997	A
5659454	Vermesse	Aug 1997	A
5665222	Heller et al.	Sep 1997	A
5707502	McCaffrey et al.	Jan 1998	A
5711001	Bussan et al.	Jan 1998	A
5711861	Ward et al.	Jan 1998	A
5724030	Urbas et al.	Mar 1998	A
5733259	Valcke et al.	Mar 1998	A
5733313	Barreras. , Sr. et al.	Mar 1998	A
5735285	Albert et al.	Apr 1998	A
5748103	Flach et al.	May 1998	A
5749907	Mann	May 1998	A
5758290	Neal et al.	May 1998	A
5772586	Heinonen et al.	Jun 1998	A
5778879	Ota et al.	Jul 1998	A
5791344	Schulman et al.	Aug 1998	A
5798961	Hey et al.	Aug 1998	A
5804047	Karube et al.	Sep 1998	A
5820551	Hill et al.	Oct 1998	A
5822715	Worthington et al.	Oct 1998	A
5830064	Bradish et al.	Nov 1998	A
5833603	Kovacs et al.	Nov 1998	A
5856758	Joffe et al.	Jan 1999	A
5891049	Cyrus et al.	Apr 1999	A
5899855	Brown	May 1999	A
5918603	Brown	Jul 1999	A
5925021	Castellano et al.	Jul 1999	A
5935224	Svancarek et al.	Aug 1999	A
5942979	Luppino	Aug 1999	A
5951485	Cyrus et al.	Sep 1999	A
5957854	Besson et al.	Sep 1999	A
5961451	Reber et al.	Oct 1999	A
5964993	Blubaugh, Jr. et al.	Oct 1999	A
5965380	Heller et al.	Oct 1999	A
5971922	Arita et al.	Oct 1999	A
5995860	Sun et al.	Nov 1999	A
6001067	Shults et al.	Dec 1999	A
6024699	Surwit et al.	Feb 2000	A
6028413	Brockmann	Feb 2000	A
6049727	Crothall	Apr 2000	A
6052565	Ishikura et al.	Apr 2000	A
6071391	Gotoh et al.	Jun 2000	A
6083710	Heller et al.	Jul 2000	A
6085342	Marholev et al.	Jul 2000	A
6088608	Schulman et al.	Jul 2000	A
6091976	Pfeiffer et al.	Jul 2000	A
6091987	Thompson	Jul 2000	A
6093172	Funderburk et al.	Jul 2000	A
6096364	Bok et al.	Aug 2000	A
6097480	Kaplan	Aug 2000	A
6103033	Say et al.	Aug 2000	A
6117290	Say et al.	Sep 2000	A
6119028	Schulman et al.	Sep 2000	A
6120676	Heller et al.	Sep 2000	A
6121009	Heller et al.	Sep 2000	A
6121611	Lindsay et al.	Sep 2000	A
6122351	Schlueter, Jr. et al.	Sep 2000	A
6130623	MacLellan et al.	Oct 2000	A
6134461	Say et al.	Oct 2000	A
6143164	Heller et al.	Nov 2000	A
6144837	Quy	Nov 2000	A
6144871	Saito et al.	Nov 2000	A
6159147	Lichter et al.	Dec 2000	A
6161095	Brown	Dec 2000	A
6162611	Heller et al.	Dec 2000	A
6175752	Say et al.	Jan 2001	B1
6198946	Shin et al.	Mar 2001	B1
6200265	Walsh et al.	Mar 2001	B1
6203495	Bardy et al.	Mar 2001	B1
6212416	Ward et al.	Apr 2001	B1
6219574	Cormier et al.	Apr 2001	B1
6233471	Berner et al.	May 2001	B1
6248067	Causey, III et al.	Jun 2001	B1
6270455	Brown	Aug 2001	B1
6275717	Gross et al.	Aug 2001	B1
6283761	Joao	Sep 2001	B1
6284478	Heller et al.	Sep 2001	B1
6291200	LeJeune et al.	Sep 2001	B1
6293925	Safabash et al.	Sep 2001	B1
6294997	Paratore et al.	Sep 2001	B1
6295506	Heinonen et al.	Sep 2001	B1
6298255	Cordero et al.	Oct 2001	B1
6299347	Pompei	Oct 2001	B1
6299757	Feldman et al.	Oct 2001	B1
6306104	Cunningham et al.	Oct 2001	B1
6309884	Cooper et al.	Oct 2001	B1
6314317	Willis	Nov 2001	B1
6329161	Heller et al.	Dec 2001	B1
6338790	Feldman et al.	Jan 2002	B1
6348640	Navot et al.	Feb 2002	B1
6359270	Bridson	Mar 2002	B1
6359444	Grimes	Mar 2002	B1
6360888	McIvor et al.	Mar 2002	B1
6366794	Moussy et al.	Apr 2002	B1
6377828	Chaiken et al.	Apr 2002	B1
6377894	Deweese et al.	Apr 2002	B1
6379301	Worthington et al.	Apr 2002	B1
6387048	Schulman et al.	May 2002	B1
6400974	Lesho	Jun 2002	B1
6405066	Essenpreis et al.	Jun 2002	B1
6413393	Van Antwerp et al.	Jul 2002	B1
6416471	Kumar et al.	Jul 2002	B1
6418346	Nelson et al.	Jul 2002	B1
6424847	Mastrototaro et al.	Jul 2002	B1
6427088	Bowman, IV et al.	Jul 2002	B1
6440068	Brown et al.	Aug 2002	B1
6461496	Feldman et al.	Oct 2002	B1
6478736	Mault	Nov 2002	B1
6484045	Holker et al.	Nov 2002	B1
6484046	Say et al.	Nov 2002	B1
6493069	Nagashimada et al.	Dec 2002	B1
6494830	Wessel	Dec 2002	B1
6496729	Thompson	Dec 2002	B2
6497655	Linberg et al.	Dec 2002	B1
6503381	Gotoh et al.	Jan 2003	B1
6514460	Fendrock	Feb 2003	B1
6514689	Han et al.	Feb 2003	B2
6514718	Heller et al.	Feb 2003	B2
6520326	McIvor et al.	Feb 2003	B2
6522927	Bishay et al.	Feb 2003	B1
6540891	Stewart et al.	Apr 2003	B1
6544212	Galley et al.	Apr 2003	B2
6549796	Sohrab	Apr 2003	B2
6551494	Heller et al.	Apr 2003	B1
6558320	Causey, III et al.	May 2003	B1
6558321	Burd et al.	May 2003	B1
6558351	Steil et al.	May 2003	B1
6560471	Heller et al.	May 2003	B1
6561975	Pool et al.	May 2003	B1
6561978	Conn et al.	May 2003	B1
6562001	Lebel et al.	May 2003	B2
6564105	Starkweather et al.	May 2003	B2
6565509	Say et al.	May 2003	B1
6571128	Lebel et al.	May 2003	B2
6574510	Von Arx et al.	Jun 2003	B2
6576101	Heller et al.	Jun 2003	B1
6577899	Lebel et al.	Jun 2003	B2
6579231	Phipps	Jun 2003	B1
6579690	Bonnecaze et al.	Jun 2003	B1
6585644	Lebel et al.	Jul 2003	B2
6591125	Buse et al.	Jul 2003	B1
6592745	Feldman et al.	Jul 2003	B1
6595919	Berner et al.	Jul 2003	B2
6600997	Deweese et al.	Jul 2003	B2
6605200	Mao et al.	Aug 2003	B1
6605201	Mao et al.	Aug 2003	B1
6607509	Bobroff et al.	Aug 2003	B2
6608562	Kimura et al.	Aug 2003	B1
6610012	Mault	Aug 2003	B2
6611206	Eshelman et al.	Aug 2003	B2
6616819	Liamos et al.	Sep 2003	B1
6618934	Feldman et al.	Sep 2003	B1
6627154	Goodman et al.	Sep 2003	B1
6633772	Ford et al.	Oct 2003	B2
6635014	Starkweather et al.	Oct 2003	B2
6635167	Batman et al.	Oct 2003	B1
6641533	Causey, III et al.	Nov 2003	B2
6645359	Bhullar et al.	Nov 2003	B1
6648821	Lebel et al.	Nov 2003	B2
6650471	Doi	Nov 2003	B2
6654625	Say et al.	Nov 2003	B1
6656114	Poulson et al.	Dec 2003	B1
6658396	Tang et al.	Dec 2003	B1
6659948	Lebel et al.	Dec 2003	B2
6662439	Bhullar	Dec 2003	B1
6668196	Villegas et al.	Dec 2003	B1
6676816	Mao et al.	Jan 2004	B2
6687546	Lebel et al.	Feb 2004	B2
6689056	Kilcoyne et al.	Feb 2004	B1
6694191	Starkweather et al.	Feb 2004	B2
6695860	Ward et al.	Feb 2004	B1
6698269	Baber et al.	Mar 2004	B2
6702857	Brauker et al.	Mar 2004	B2
6730200	Stewart et al.	May 2004	B1
6731976	Penn et al.	May 2004	B2
6733446	Lebel et al.	May 2004	B2
6735183	O'Toole et al.	May 2004	B2
6735479	Fabian et al.	May 2004	B2
6736957	Forrow et al.	May 2004	B1
6740075	Lebel et al.	May 2004	B2
6741877	Shults et al.	May 2004	B1
6746582	Heller et al.	Jun 2004	B2
6748445	Darcey et al.	Jun 2004	B1
6749740	Liamos et al.	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6764581	Forrow et al.	Jul 2004	B1
6767440	Bhullar et al.	Jul 2004	B1
6770030	Schaupp et al.	Aug 2004	B1
6773671	Lewis et al.	Aug 2004	B1
6781522	Sleva et al.	Aug 2004	B2
6790178	Mault et al.	Sep 2004	B1
6804558	Haller et al.	Oct 2004	B2
6804561	Stover	Oct 2004	B2
6809653	Mann et al.	Oct 2004	B1
6810290	Lebel et al.	Oct 2004	B2
6811533	Lebel et al.	Nov 2004	B2
6811534	Bowman, IV et al.	Nov 2004	B2
6813519	Lebel et al.	Nov 2004	B2
6850790	Berner et al.	Feb 2005	B2
6862465	Shults et al.	Mar 2005	B2
6873268	Lebel et al.	Mar 2005	B2
6878112	Linberg et al.	Apr 2005	B2
6881551	Heller et al.	Apr 2005	B2
6892085	McIvor et al.	May 2005	B2
6893545	Gotoh et al.	May 2005	B2
6895263	Shin et al.	May 2005	B2
6895265	Silver	May 2005	B2
6923764	Aceti et al.	Aug 2005	B2
6931327	Goode, Jr. et al.	Aug 2005	B2
6932892	Chen et al.	Aug 2005	B2
6932894	Mao et al.	Aug 2005	B2
6936006	Sabra	Aug 2005	B2
6937222	Numao	Aug 2005	B2
6940403	Kail, IV	Sep 2005	B2
6941163	Ford et al.	Sep 2005	B2
6942518	Liamos et al.	Sep 2005	B2
6950708	Bowman, IV et al.	Sep 2005	B2
6958705	Lebel et al.	Oct 2005	B2
6968294	Gutta et al.	Nov 2005	B2
6971274	Olin	Dec 2005	B2
6973706	Say et al.	Dec 2005	B2
6974437	Lebel et al.	Dec 2005	B2
6983867	Fugere	Jan 2006	B1
6990366	Say et al.	Jan 2006	B2
6997907	Safabash et al.	Feb 2006	B2
6998247	Monfre et al.	Feb 2006	B2
7003336	Holker et al.	Feb 2006	B2
7003340	Say et al.	Feb 2006	B2
7003341	Say et al.	Feb 2006	B2
7009511	Mazar et al.	Mar 2006	B2
7020508	Stivoric et al.	Mar 2006	B2
7022072	Fox et al.	Apr 2006	B2
7024236	Ford et al.	Apr 2006	B2
7024245	Lebel et al.	Apr 2006	B2
7027931	Jones et al.	Apr 2006	B1
7029444	Shin et al.	Apr 2006	B2
7041068	Freeman et al.	May 2006	B2
7041468	Drucker et al.	May 2006	B2
7043305	KenKnight et al.	May 2006	B2
7052483	Wojcik	May 2006	B2
7056302	Douglas	Jun 2006	B2
7058453	Nelson et al.	Jun 2006	B2
7060031	Webb et al.	Jun 2006	B2
7073246	Bhullar et al.	Jul 2006	B2
7074307	Simpson et al.	Jul 2006	B2
7081195	Simpson et al.	Jul 2006	B2
7082334	Boute et al.	Jul 2006	B2
7098803	Mann et al.	Aug 2006	B2
7108778	Simpson et al.	Sep 2006	B2
7110803	Shults et al.	Sep 2006	B2
7113821	Sun et al.	Sep 2006	B1
7118667	Lee	Oct 2006	B2
7124027	Ernst et al.	Oct 2006	B1
7125382	Zhou et al.	Oct 2006	B2
7134999	Brauker et al.	Nov 2006	B2
7136689	Shults et al.	Nov 2006	B2
7154398	Chen et al.	Dec 2006	B2
7155290	Von Arx et al.	Dec 2006	B2
7167818	Brown	Jan 2007	B2
7171274	Starkweather et al.	Jan 2007	B2
7190988	Say et al.	Mar 2007	B2
7192450	Brauker et al.	Mar 2007	B2
7198606	Boecker et al.	Apr 2007	B2
7203549	Schommer et al.	Apr 2007	B2
7207974	Safabash et al.	Apr 2007	B2
7225535	Feldman et al.	Jun 2007	B2
7226442	Sheppard et al.	Jun 2007	B2
7226978	Tapsak et al.	Jun 2007	B2
7228162	Ward et al.	Jun 2007	B2
7228182	Healy et al.	Jun 2007	B2
7237712	DeRocco et al.	Jul 2007	B2
7267665	Steil et al.	Sep 2007	B2
7276029	Goode, Jr. et al.	Oct 2007	B2
7276146	Wilsey	Oct 2007	B2
7276147	Wilsey	Oct 2007	B2
7278983	Ireland et al.	Oct 2007	B2
7286894	Grant et al.	Oct 2007	B1
7287318	Bhullar et al.	Oct 2007	B2
7291497	Holmes et al.	Nov 2007	B2
7295867	Berner et al.	Nov 2007	B2
7299082	Feldman et al.	Nov 2007	B2
7310544	Brister et al.	Dec 2007	B2
7318816	Bobroff et al.	Jan 2008	B2
7324850	Persen et al.	Jan 2008	B2
7335294	Heller et al.	Feb 2008	B2
7347819	Lebel et al.	Mar 2008	B2
7354420	Steil et al.	Apr 2008	B2
7364592	Carr/Brendel et al.	Apr 2008	B2
7366556	Brister et al.	Apr 2008	B2
7379765	Petisce et al.	May 2008	B2
7384397	Zhang et al.	Jun 2008	B2
7386937	Bhullar et al.	Jun 2008	B2
7387010	Sunshine et al.	Jun 2008	B2
7399277	Saidara et al.	Jul 2008	B2
7401111	Batman et al.	Jul 2008	B1
7402153	Steil et al.	Jul 2008	B2
7404796	Ginsberg	Jul 2008	B2
7408132	Wambsganss et al.	Aug 2008	B2
7419573	Gundel	Sep 2008	B2
7424318	Brister et al.	Sep 2008	B2
7460898	Brister et al.	Dec 2008	B2
7467003	Brister et al.	Dec 2008	B2
7471972	Rhodes et al.	Dec 2008	B2
7492254	Bandy et al.	Feb 2009	B2
7494465	Brister et al.	Feb 2009	B2
7497827	Brister et al.	Mar 2009	B2
7519408	Rasdal et al.	Apr 2009	B2
7547281	Hayes et al.	Jun 2009	B2
7565197	Haubrich et al.	Jul 2009	B2
7569030	Lebel et al.	Aug 2009	B2
7574266	Dudding et al.	Aug 2009	B2
7583990	Goode, Jr. et al.	Sep 2009	B2
7591801	Brauker et al.	Sep 2009	B2
7599726	Goode, Jr. et al.	Oct 2009	B2
7602310	Mann et al.	Oct 2009	B2
7604178	Stewart	Oct 2009	B2
7613491	Boock et al.	Nov 2009	B2
7615007	Shults et al.	Nov 2009	B2
7618369	Hayter et al.	Nov 2009	B2
7632228	Brauker et al.	Dec 2009	B2
7637868	Saint et al.	Dec 2009	B2
7640048	Dobbies et al.	Dec 2009	B2
7651596	Petisce et al.	Jan 2010	B2
7653425	Hayter et al.	Jan 2010	B2
7654956	Brister et al.	Feb 2010	B2
7657297	Simpson et al.	Feb 2010	B2
7659823	Killian et al.	Feb 2010	B1
7668596	Von Arx et al.	Feb 2010	B2
7699775	Desai et al.	Apr 2010	B2
7701052	Borland et al.	Apr 2010	B2
7711402	Shults et al.	May 2010	B2
7713574	Brister et al.	May 2010	B2
7715893	Kamath et al.	May 2010	B2
7741734	Joannopoulos et al.	Jun 2010	B2
7768387	Fennell et al.	Aug 2010	B2
7771352	Shults et al.	Aug 2010	B2
7774145	Brauker et al.	Aug 2010	B2
7778680	Goode, Jr. et al.	Aug 2010	B2
7779332	Karr et al.	Aug 2010	B2
7782192	Jeckelmann et al.	Aug 2010	B2
7783333	Brister et al.	Aug 2010	B2
7791467	Mazar et al.	Sep 2010	B2
7792562	Shults et al.	Sep 2010	B2
7813809	Strother et al.	Oct 2010	B2
7826981	Goode, Jr. et al.	Nov 2010	B2
7831310	Lebel et al.	Nov 2010	B2
7833151	Khait et al.	Nov 2010	B2
7860574	Von Arx et al.	Dec 2010	B2
7866026	Wang et al.	Jan 2011	B1
7882611	Shah et al.	Feb 2011	B2
7889069	Fifolt et al.	Feb 2011	B2
7899511	Shults et al.	Mar 2011	B2
7905833	Brister et al.	Mar 2011	B2
7912655	Power et al.	Mar 2011	B2
7912674	Killoren Clark et al.	Mar 2011	B2
7914450	Goode, Jr. et al.	Mar 2011	B2
7916013	Stevenson	Mar 2011	B2
7955258	Goscha et al.	Jun 2011	B2
7970448	Shults et al.	Jun 2011	B2
7974672	Shults et al.	Jul 2011	B2
7976467	Young et al.	Jul 2011	B2
7978063	Baldus et al.	Jul 2011	B2
7999674	Kamen	Aug 2011	B2
8000918	Fjield et al.	Aug 2011	B2
8072310	Everhart	Dec 2011	B1
8090445	Ginggen	Jan 2012	B2
8093991	Stevenson et al.	Jan 2012	B2
8094009	Allen et al.	Jan 2012	B2
8098159	Batra et al.	Jan 2012	B2
8098160	Howarth et al.	Jan 2012	B2
8098161	Lavedas	Jan 2012	B2
8098201	Choi et al.	Jan 2012	B2
8098208	Ficker et al.	Jan 2012	B2
8102021	Degani	Jan 2012	B2
8102154	Bishop et al.	Jan 2012	B2
8102263	Yeo et al.	Jan 2012	B2
8102789	Rosar et al.	Jan 2012	B2
8103241	Young et al.	Jan 2012	B2
8103325	Swedlow et al.	Jan 2012	B2
8111042	Bennett	Feb 2012	B2
8115488	McDowell	Feb 2012	B2
8116681	Baarman	Feb 2012	B2
8116683	Baarman	Feb 2012	B2
8117481	Anselmi et al.	Feb 2012	B2
8120493	Burr	Feb 2012	B2
8124452	Sheats	Feb 2012	B2
8130093	Mazar et al.	Mar 2012	B2
8131351	Kalgren et al.	Mar 2012	B2
8131365	Zhang et al.	Mar 2012	B2
8131565	Dicks et al.	Mar 2012	B2
8132037	Fehr et al.	Mar 2012	B2
8135352	Langsweirdt et al.	Mar 2012	B2
8136735	Arai et al.	Mar 2012	B2
8138925	Downie et al.	Mar 2012	B2
8140160	Pless et al.	Mar 2012	B2
8140168	Olson et al.	Mar 2012	B2
8140299	Siess	Mar 2012	B2
8150321	Winter et al.	Apr 2012	B2
8150516	Levine et al.	Apr 2012	B2
8179266	Hermle	May 2012	B2
8538512	Bibian et al.	Sep 2013	B1
8617069	Bernstein et al.	Dec 2013	B2
8808515	Feldman et al.	Aug 2014	B2
9736210	Root et al.	Aug 2017	B2
20010016682	Berner et al.	Aug 2001	A1
20010037060	Thompson et al.	Nov 2001	A1
20010037366	Webb et al.	Nov 2001	A1
20010047127	New et al.	Nov 2001	A1
20020013522	Lay et al.	Jan 2002	A1
20020013538	Teller	Jan 2002	A1
20020019022	Dunn et al.	Feb 2002	A1
20020019584	Schulze et al.	Feb 2002	A1
20020019586	Teller et al.	Feb 2002	A1
20020019606	Lebel et al.	Feb 2002	A1
20020023852	McIvor et al.	Feb 2002	A1
20020039026	Stroth et al.	Apr 2002	A1
20020042090	Heller et al.	Apr 2002	A1
20020045808	Ford et al.	Apr 2002	A1
20020049482	Fabian et al.	Apr 2002	A1
20020050250	Peterson et al.	May 2002	A1
20020065454	Lebel et al.	May 2002	A1
20020072784	Sheppard et al.	Jun 2002	A1
20020074162	Su et al.	Jun 2002	A1
20020084196	Liamos et al.	Jul 2002	A1
20020091796	Higginson et al.	Jul 2002	A1
20020093969	Lin et al.	Jul 2002	A1
20020103499	Perez et al.	Aug 2002	A1
20020106709	Potts et al.	Aug 2002	A1
20020118528	Su et al.	Aug 2002	A1
20020128594	Das et al.	Sep 2002	A1
20020161288	Shin et al.	Oct 2002	A1
20020164836	Ho	Nov 2002	A1
20020169635	Shillingburg	Nov 2002	A1
20020183604	Gowda et al.	Dec 2002	A1
20020185128	Theobald	Dec 2002	A1
20020185130	Wright et al.	Dec 2002	A1
20020197522	Lawrence et al.	Dec 2002	A1
20030004403	Drinan et al.	Jan 2003	A1
20030020477	Goldstein	Jan 2003	A1
20030023317	Brauker et al.	Jan 2003	A1
20030023461	Quintanilla et al.	Jan 2003	A1
20030032867	Crothall et al.	Feb 2003	A1
20030032874	Rhodes et al.	Feb 2003	A1
20030042137	Mao et al.	Mar 2003	A1
20030060692	Ruchti et al.	Mar 2003	A1
20030065308	Lebel et al.	Apr 2003	A1
20030076792	Theimer	Apr 2003	A1
20030078481	McIvor et al.	Apr 2003	A1
20030100040	Bonnecaze et al.	May 2003	A1
20030100821	Heller et al.	May 2003	A1
20030114897	Von Arx et al.	Jun 2003	A1
20030114898	Von Arx et al.	Jun 2003	A1
20030119457	Standke	Jun 2003	A1
20030125612	Fox et al.	Jul 2003	A1
20030130616	Steil et al.	Jul 2003	A1
20030134347	Heller et al.	Jul 2003	A1
20030144579	Buss	Jul 2003	A1
20030144581	Conn et al.	Jul 2003	A1
20030168338	Gao et al.	Sep 2003	A1
20030176933	Lebel et al.	Sep 2003	A1
20030187338	Say et al.	Oct 2003	A1
20030188427	Say et al.	Oct 2003	A1
20030199790	Boecker et al.	Oct 2003	A1
20030204290	Sadler et al.	Oct 2003	A1
20030208113	Mault et al.	Nov 2003	A1
20030208114	Ackerman	Nov 2003	A1
20030212317	Kovatchev et al.	Nov 2003	A1
20030212379	Bylund et al.	Nov 2003	A1
20030212579	Brown et al.	Nov 2003	A1
20030216621	Alpert et al.	Nov 2003	A1
20030216630	Jersey/Willuhn et al.	Nov 2003	A1
20030217966	Tapsak et al.	Nov 2003	A1
20040010207	Flaherty et al.	Jan 2004	A1
20040011671	Shults et al.	Jan 2004	A1
20040017300	Kotzin et al.	Jan 2004	A1
20040030226	Quy	Feb 2004	A1
20040030531	Miller et al.	Feb 2004	A1
20040030581	Levin et al.	Feb 2004	A1
20040039255	Simonsen et al.	Feb 2004	A1
20040039298	Abreu	Feb 2004	A1
20040040840	Mao et al.	Mar 2004	A1
20040045879	Shults et al.	Mar 2004	A1
20040054263	Moerman et al.	Mar 2004	A1
20040060818	Feldman et al.	Apr 2004	A1
20040063435	Sakamoto et al.	Apr 2004	A1
20040064068	DeNuzzio et al.	Apr 2004	A1
20040100376	Lye et al.	May 2004	A1
20040105411	Boatwright et al.	Jun 2004	A1
20040106858	Say et al.	Jun 2004	A1
20040122353	Shahmirian et al.	Jun 2004	A1
20040133164	Funderburk et al.	Jul 2004	A1
20040135684	Steinthal et al.	Jul 2004	A1
20040138588	Saikiey et al.	Jul 2004	A1
20040146909	Duong et al.	Jul 2004	A1
20040152622	Keith et al.	Aug 2004	A1
20040167801	Say et al.	Aug 2004	A1
20040171921	Say et al.	Sep 2004	A1
20040176672	Silver et al.	Sep 2004	A1
20040186362	Brauker et al.	Sep 2004	A1
20040186365	Jin et al.	Sep 2004	A1
20040193020	Chiba et al.	Sep 2004	A1
20040193025	Steil et al.	Sep 2004	A1
20040193090	Lebel et al.	Sep 2004	A1
20040197846	Hockersmith et al.	Oct 2004	A1
20040199056	Husemann et al.	Oct 2004	A1
20040199059	Brauker et al.	Oct 2004	A1
20040204635	Scharf	Oct 2004	A1
20040204687	Mogensen et al.	Oct 2004	A1
20040204744	Penner et al.	Oct 2004	A1
20040204868	Maynard et al.	Oct 2004	A1
20040206625	Bhullar et al.	Oct 2004	A1
20040206916	Colvin, Jr. et al.	Oct 2004	A1
20040221057	Darcey et al.	Nov 2004	A1
20040223876	Kirollos et al.	Nov 2004	A1
20040225199	Evanyk et al.	Nov 2004	A1
20040225338	Lebel et al.	Nov 2004	A1
20040236200	Say et al.	Nov 2004	A1
20040240426	Wu et al.	Dec 2004	A1
20040249999	Connolly et al.	Dec 2004	A1
20040254433	Bandis et al.	Dec 2004	A1
20040254434	Goodnow et al.	Dec 2004	A1
20040267300	Mace	Dec 2004	A1
20050001024	Kusaka et al.	Jan 2005	A1
20050003470	Nelson et al.	Jan 2005	A1
20050004439	Shin et al.	Jan 2005	A1
20050004494	Perez et al.	Jan 2005	A1
20050010269	Lebel et al.	Jan 2005	A1
20050017864	Tsoukalis	Jan 2005	A1
20050027177	Shin et al.	Feb 2005	A1
20050027180	Goode, Jr. et al.	Feb 2005	A1
20050027181	Goode, Jr. et al.	Feb 2005	A1
20050027463	Goode, Jr. et al.	Feb 2005	A1
20050031689	Shults et al.	Feb 2005	A1
20050038332	Saidara et al.	Feb 2005	A1
20050043598	Goode, Jr. et al.	Feb 2005	A1
20050090607	Tapsak et al.	Apr 2005	A1
20050096511	Fox et al.	May 2005	A1
20050096512	Fox et al.	May 2005	A1
20050103624	Bhullar et al.	May 2005	A1
20050104457	Jordan et al.	May 2005	A1
20050112169	Brauker et al.	May 2005	A1
20050112544	Xu et al.	May 2005	A1
20050113653	Fox et al.	May 2005	A1
20050113886	Fischell et al.	May 2005	A1
20050114068	Chey et al.	May 2005	A1
20050116683	Cheng et al.	Jun 2005	A1
20050121322	Say et al.	Jun 2005	A1
20050131346	Douglas	Jun 2005	A1
20050137488	Henry et al.	Jun 2005	A1
20050137530	Campbell et al.	Jun 2005	A1
20050143635	Kamath et al.	Jun 2005	A1
20050171442	Shirasaki et al.	Aug 2005	A1
20050176136	Burd et al.	Aug 2005	A1
20050177398	Watanabe et al.	Aug 2005	A1
20050181010	Hunter et al.	Aug 2005	A1
20050182306	Sloan	Aug 2005	A1
20050182358	Veit et al.	Aug 2005	A1
20050187720	Goode, Jr. et al.	Aug 2005	A1
20050192494	Ginsberg	Sep 2005	A1
20050192557	Brauker et al.	Sep 2005	A1
20050195930	Spital et al.	Sep 2005	A1
20050199494	Say et al.	Sep 2005	A1
20050203360	Brauker et al.	Sep 2005	A1
20050204134	Von Arx et al.	Sep 2005	A1
20050215871	Feldman et al.	Sep 2005	A1
20050221504	Petruno et al.	Oct 2005	A1
20050236361	Ufer et al.	Oct 2005	A1
20050239154	Feldman et al.	Oct 2005	A1
20050239156	Drucker et al.	Oct 2005	A1
20050241957	Mao et al.	Nov 2005	A1
20050245795	Goode, Jr. et al.	Nov 2005	A1
20050245799	Brauker et al.	Nov 2005	A1
20050245839	Stivoric et al.	Nov 2005	A1
20050245904	Estes et al.	Nov 2005	A1
20050247319	Berger	Nov 2005	A1
20050251033	Scarantino et al.	Nov 2005	A1
20050261563	Zhou et al.	Nov 2005	A1
20050277164	Drucker et al.	Dec 2005	A1
20050284758	Funke et al.	Dec 2005	A1
20050287620	Heller et al.	Dec 2005	A1
20060001538	Kraft et al.	Jan 2006	A1
20060004270	Bedard et al.	Jan 2006	A1
20060004272	Shah et al.	Jan 2006	A1
20060009727	O'Mahony et al.	Jan 2006	A1
20060010098	Goodnow et al.	Jan 2006	A1
20060012464	Nitzan et al.	Jan 2006	A1
20060015020	Neale et al.	Jan 2006	A1
20060015024	Brister et al.	Jan 2006	A1
20060016700	Brister et al.	Jan 2006	A1
20060019327	Brister et al.	Jan 2006	A1
20060020186	Brister et al.	Jan 2006	A1
20060020187	Brister et al.	Jan 2006	A1
20060020188	Kamath et al.	Jan 2006	A1
20060020189	Brister et al.	Jan 2006	A1
20060020190	Kamath et al.	Jan 2006	A1
20060020191	Brister et al.	Jan 2006	A1
20060020192	Brister et al.	Jan 2006	A1
20060020300	Nghiem et al.	Jan 2006	A1
20060025662	Buse et al.	Feb 2006	A1
20060025663	Talbot et al.	Feb 2006	A1
20060029177	Cranford, Jr. et al.	Feb 2006	A1
20060031094	Cohen et al.	Feb 2006	A1
20060036139	Brister et al.	Feb 2006	A1
20060036140	Brister et al.	Feb 2006	A1
20060036141	Kamath et al.	Feb 2006	A1
20060036142	Brister et al.	Feb 2006	A1
20060036143	Brister et al.	Feb 2006	A1
20060036144	Brister et al.	Feb 2006	A1
20060036145	Brister et al.	Feb 2006	A1
20060040793	Martens et al.	Feb 2006	A1
20060042080	Say et al.	Mar 2006	A1
20060049359	Busta et al.	Mar 2006	A1
20060058588	Zdeblick	Mar 2006	A1
20060064035	Wang et al.	Mar 2006	A1
20060091006	Wang et al.	May 2006	A1
20060129733	Solbelman	Jun 2006	A1
20060142651	Brister et al.	Jun 2006	A1
20060154642	Scannell	Jul 2006	A1
20060155180	Brister et al.	Jul 2006	A1
20060166629	Reggiardo	Jul 2006	A1
20060173260	Gaoni et al.	Aug 2006	A1
20060173406	Hayes et al.	Aug 2006	A1
20060173444	Choy et al.	Aug 2006	A1
20060183984	Dobbies et al.	Aug 2006	A1
20060183985	Brister et al.	Aug 2006	A1
20060189863	Peyser et al.	Aug 2006	A1
20060193375	Lee et al.	Aug 2006	A1
20060200981	Bhullar et al.	Sep 2006	A1
20060200982	Bhullar et al.	Sep 2006	A1
20060202805	Schulman et al.	Sep 2006	A1
20060202859	Mastrototaro et al.	Sep 2006	A1
20060220839	Fifolt et al.	Oct 2006	A1
20060222566	Brauker et al.	Oct 2006	A1
20060224059	Swedlow	Oct 2006	A1
20060224109	Steil et al.	Oct 2006	A1
20060224141	Rush et al.	Oct 2006	A1
20060226985	Goodnow et al.	Oct 2006	A1
20060229512	Petisce et al.	Oct 2006	A1
20060233839	Jacquet	Oct 2006	A1
20060247508	Fennell	Nov 2006	A1
20060247710	Goetz et al.	Nov 2006	A1
20060248398	Neel et al.	Nov 2006	A1
20060253085	Geismar et al.	Nov 2006	A1
20060253086	Moberg et al.	Nov 2006	A1
20060264785	Dring et al.	Nov 2006	A1
20060264888	Moberg et al.	Nov 2006	A1
20060270922	Brauker et al.	Nov 2006	A1
20060272652	Stocker et al.	Dec 2006	A1
20060276714	Holt et al.	Dec 2006	A1
20060287586	Murphy	Dec 2006	A1
20060287591	Ocvirk et al.	Dec 2006	A1
20060287691	Drew	Dec 2006	A1
20060290496	Peeters et al.	Dec 2006	A1
20060293607	Alt et al.	Dec 2006	A1
20070016381	Kamath et al.	Jan 2007	A1
20070017983	Frank et al.	Jan 2007	A1
20070027381	Stafford	Feb 2007	A1
20070027507	Burdett et al.	Feb 2007	A1
20070030154	Aiki et al.	Feb 2007	A1
20070032706	Kamath et al.	Feb 2007	A1
20070033074	Nitzan et al.	Feb 2007	A1
20070038044	Dobbles et al.	Feb 2007	A1
20070055799	Koehler et al.	Mar 2007	A1
20070056858	Chen et al.	Mar 2007	A1
20070059196	Brister et al.	Mar 2007	A1
20070060814	Stafford	Mar 2007	A1
20070066873	Kamath et al.	Mar 2007	A1
20070068807	Feldman et al.	Mar 2007	A1
20070071681	Gadkar et al.	Mar 2007	A1
20070073129	Shah et al.	Mar 2007	A1
20070078320	Stafford	Apr 2007	A1
20070078321	Mazza et al.	Apr 2007	A1
20070078322	Stafford	Apr 2007	A1
20070078323	Reggiardo et al.	Apr 2007	A1
20070090511	Borland et al.	Apr 2007	A1
20070095661	Wang et al.	May 2007	A1
20070100218	Sweitzer et al.	May 2007	A1
20070100222	Mastrototaro et al.	May 2007	A1
20070106133	Satchwell et al.	May 2007	A1
20070106135	Sloan et al.	May 2007	A1
20070108048	Wang et al.	May 2007	A1
20070111196	Alarcon et al.	May 2007	A1
20070124002	Estes et al.	May 2007	A1
20070129621	Kellogg et al.	Jun 2007	A1
20070149875	Ouyang et al.	Jun 2007	A1
20070156033	Causey, III et al.	Jul 2007	A1
20070163880	Woo et al.	Jul 2007	A1
20070168224	Letzt et al.	Jul 2007	A1
20070173706	Neinast et al.	Jul 2007	A1
20070173761	Kanderian et al.	Jul 2007	A1
20070179349	Hoy et al.	Aug 2007	A1
20070179352	Randlov et al.	Aug 2007	A1
20070191701	Feldman et al.	Aug 2007	A1
20070197889	Brister et al.	Aug 2007	A1
20070199818	Petyt et al.	Aug 2007	A1
20070203407	Hoss et al.	Aug 2007	A1
20070203966	Brauker et al.	Aug 2007	A1
20070219496	Kamen et al.	Sep 2007	A1
20070222609	Duron et al.	Sep 2007	A1
20070227911	Wang et al.	Oct 2007	A1
20070232880	Siddiqui et al.	Oct 2007	A1
20070233013	Schoenberg et al.	Oct 2007	A1
20070235331	Simpson et al.	Oct 2007	A1
20070244383	Talbot et al.	Oct 2007	A1
20070249922	Peyser et al.	Oct 2007	A1
20070253021	Mehta et al.	Nov 2007	A1
20070255125	Moberg et al.	Nov 2007	A1
20070255348	Holtzclaw	Nov 2007	A1
20070255531	Drew	Nov 2007	A1
20070258395	Jollota et al.	Nov 2007	A1
20070270672	Hayter	Nov 2007	A1
20070282299	Hellwig	Dec 2007	A1
20070285238	Batra	Dec 2007	A1
20080009304	Fry	Jan 2008	A1
20080009692	Stafford	Jan 2008	A1
20080009805	Ethelfeld	Jan 2008	A1
20080017522	Heller et al.	Jan 2008	A1
20080018433	Pitt/Pladdy	Jan 2008	A1
20080021666	Goode, Jr. et al.	Jan 2008	A1
20080029391	Mao et al.	Feb 2008	A1
20080030369	Mann et al.	Feb 2008	A1
20080033254	Kamath et al.	Feb 2008	A1
20080033268	Stafford et al.	Feb 2008	A1
20080039702	Hayter et al.	Feb 2008	A1
20080045824	Tapsak et al.	Feb 2008	A1
20080055070	Bange et al.	Mar 2008	A1
20080058625	McGarraugh et al.	Mar 2008	A1
20080059227	Clapp	Mar 2008	A1
20080060955	Goodnow	Mar 2008	A1
20080062055	Cunningham et al.	Mar 2008	A1
20080064937	McGarraugh et al.	Mar 2008	A1
20080064943	Talbot et al.	Mar 2008	A1
20080066305	Wang et al.	Mar 2008	A1
20080067627	Boeck et al.	Mar 2008	A1
20080071156	Brister et al.	Mar 2008	A1
20080071157	McGarraugh et al.	Mar 2008	A1
20080071158	McGarraugh et al.	Mar 2008	A1
20080071328	Haubrich et al.	Mar 2008	A1
20080071580	Marcus	Mar 2008	A1
20080081977	Hayter et al.	Apr 2008	A1
20080083617	Simpson et al.	Apr 2008	A1
20080086042	Brister et al.	Apr 2008	A1
20080086044	Brister et al.	Apr 2008	A1
20080086273	Shults et al.	Apr 2008	A1
20080092638	Brenneman et al.	Apr 2008	A1
20080097289	Steil et al.	Apr 2008	A1
20080097908	Dicks et al.	Apr 2008	A1
20080102441	Chen et al.	May 2008	A1
20080108942	Brister et al.	May 2008	A1
20080119705	Patel et al.	May 2008	A1
20080139910	Mastrototaro et al.	Jun 2008	A1
20080148873	Wang	Jun 2008	A1
20080154513	Kovatchev et al.	Jun 2008	A1
20080161664	Mastrototaro et al.	Jul 2008	A1
20080161666	Feldman et al.	Jul 2008	A1
20080167543	Say et al.	Jul 2008	A1
20080167572	Stivoric et al.	Jul 2008	A1
20080172205	Breton et al.	Jul 2008	A1
20080179187	Ouyang	Jul 2008	A1
20080182537	Manku et al.	Jul 2008	A1
20080183060	Steil et al.	Jul 2008	A1
20080183061	Goode et al.	Jul 2008	A1
20080183399	Goode et al.	Jul 2008	A1
20080188731	Brister et al.	Aug 2008	A1
20080188796	Steil et al.	Aug 2008	A1
20080189051	Goode et al.	Aug 2008	A1
20080194926	Goh et al.	Aug 2008	A1
20080194934	Ray et al.	Aug 2008	A1
20080194935	Brister et al.	Aug 2008	A1
20080194936	Goode et al.	Aug 2008	A1
20080194937	Goode et al.	Aug 2008	A1
20080194938	Brister et al.	Aug 2008	A1
20080195232	Car/Brendel et al.	Aug 2008	A1
20080195967	Goode et al.	Aug 2008	A1
20080197024	Simpson et al.	Aug 2008	A1
20080200788	Brister et al.	Aug 2008	A1
20080200789	Brister et al.	Aug 2008	A1
20080200791	Simpson et al.	Aug 2008	A1
20080208025	Shults et al.	Aug 2008	A1
20080208113	Damiano et al.	Aug 2008	A1
20080214915	Brister et al.	Sep 2008	A1
20080214918	Brister et al.	Sep 2008	A1
20080228051	Shults et al.	Sep 2008	A1
20080228054	Shults et al.	Sep 2008	A1
20080234992	Ray et al.	Sep 2008	A1
20080235469	Drew	Sep 2008	A1
20080242961	Brister et al.	Oct 2008	A1
20080242962	Roesicke et al.	Oct 2008	A1
20080255434	Hayter et al.	Oct 2008	A1
20080255437	Hayter	Oct 2008	A1
20080255438	Saidara et al.	Oct 2008	A1
20080255808	Hayter	Oct 2008	A1
20080256048	Hayter	Oct 2008	A1
20080262469	Brister et al.	Oct 2008	A1
20080267823	Wang et al.	Oct 2008	A1
20080275313	Brister et al.	Nov 2008	A1
20080275327	Faarbaek et al.	Nov 2008	A1
20080278333	Fennell et al.	Nov 2008	A1
20080287755	Sass et al.	Nov 2008	A1
20080287761	Hayter	Nov 2008	A1
20080287762	Hayter	Nov 2008	A1
20080287763	Hayter	Nov 2008	A1
20080287764	Rasdal et al.	Nov 2008	A1
20080287765	Rasdal et al.	Nov 2008	A1
20080287766	Rasdal et al.	Nov 2008	A1
20080288180	Hayter	Nov 2008	A1
20080288204	Hayter et al.	Nov 2008	A1
20080294024	Cosentino et al.	Nov 2008	A1
20080296155	Shults et al.	Dec 2008	A1
20080300572	Rankers	Dec 2008	A1
20080306368	Goode et al.	Dec 2008	A1
20080306434	Dobbles et al.	Dec 2008	A1
20080306435	Kamath et al.	Dec 2008	A1
20080306444	Brister et al.	Dec 2008	A1
20080312518	Jina et al.	Dec 2008	A1
20080312841	Hayter	Dec 2008	A1
20080312842	Hayter	Dec 2008	A1
20080312844	Hayter et al.	Dec 2008	A1
20080312845	Hayter et al.	Dec 2008	A1
20090005665	Hayter et al.	Jan 2009	A1
20090005666	Shin et al.	Jan 2009	A1
20090006034	Hayter et al.	Jan 2009	A1
20090006133	Weinert et al.	Jan 2009	A1
20090012379	Goode et al.	Jan 2009	A1
20090018424	Kamath et al.	Jan 2009	A1
20090018425	Ouyang et al.	Jan 2009	A1
20090020502	Bhullar et al.	Jan 2009	A1
20090030294	Petisce et al.	Jan 2009	A1
20090033482	Hayter et al.	Feb 2009	A1
20090036747	Hayter et al.	Feb 2009	A1
20090036758	Brauker et al.	Feb 2009	A1
20090036760	Hayter	Feb 2009	A1
20090036763	Brauker et al.	Feb 2009	A1
20090043181	Brauker et al.	Feb 2009	A1
20090043182	Brauker et al.	Feb 2009	A1
20090043525	Brauker et al.	Feb 2009	A1
20090043541	Brauker et al.	Feb 2009	A1
20090043542	Brauker et al.	Feb 2009	A1
20090045055	Rhodes et al.	Feb 2009	A1
20090048503	Dalal et al.	Feb 2009	A1
20090054748	Feldman et al.	Feb 2009	A1
20090055149	Hayter et al.	Feb 2009	A1
20090058635	LaLonde et al.	Mar 2009	A1
20090062633	Brauker et al.	Mar 2009	A1
20090062635	Brauker et al.	Mar 2009	A1
20090062767	VanAntwerp et al.	Mar 2009	A1
20090063187	Johnson et al.	Mar 2009	A1
20090063402	Hayter	Mar 2009	A1
20090076356	Simpson et al.	Mar 2009	A1
20090076359	Peyser et al.	Mar 2009	A1
20090076360	Brister et al.	Mar 2009	A1
20090076361	Kamath et al.	Mar 2009	A1
20090085768	Patel et al.	Apr 2009	A1
20090085873	Betts et al.	Apr 2009	A1
20090099436	Brister et al.	Apr 2009	A1
20090105554	Stahmann et al.	Apr 2009	A1
20090105560	Solomon	Apr 2009	A1
20090105636	Hayter et al.	Apr 2009	A1
20090112478	Mueller, Jr. et al.	Apr 2009	A1
20090124877	Goode et al.	May 2009	A1
20090124878	Goode et al.	May 2009	A1
20090124879	Brister et al.	May 2009	A1
20090124964	Leach et al.	May 2009	A1
20090131768	Simpson et al.	May 2009	A1
20090131769	Leach et al.	May 2009	A1
20090131776	Simpson et al.	May 2009	A1
20090131777	Simpson et al.	May 2009	A1
20090131860	Nielsen	May 2009	A1
20090137886	Shariati et al.	May 2009	A1
20090137887	Shariati et al.	May 2009	A1
20090143659	Li et al.	Jun 2009	A1
20090143660	Brister et al.	Jun 2009	A1
20090149728	Van Antwerp et al.	Jun 2009	A1
20090150186	Cohen et al.	Jun 2009	A1
20090156919	Brister et al.	Jun 2009	A1
20090156924	Shariati et al.	Jun 2009	A1
20090163790	Brister et al.	Jun 2009	A1
20090163791	Brister et al.	Jun 2009	A1
20090164190	Hayter	Jun 2009	A1
20090164239	Hayter et al.	Jun 2009	A1
20090164251	Hayter	Jun 2009	A1
20090178459	Li et al.	Jul 2009	A1
20090182217	Li et al.	Jul 2009	A1
20090189738	Hermle	Jul 2009	A1
20090192366	Mensinger et al.	Jul 2009	A1
20090192380	Shariati et al.	Jul 2009	A1
20090192722	Shariati et al.	Jul 2009	A1
20090192724	Brauker et al.	Jul 2009	A1
20090192745	Kamath et al.	Jul 2009	A1
20090192751	Kamath et al.	Jul 2009	A1
20090198118	Hayter et al.	Aug 2009	A1
20090203981	Brauker et al.	Aug 2009	A1
20090204340	Feldman et al.	Aug 2009	A1
20090204341	Brauker et al.	Aug 2009	A1
20090210249	Rasch/Menges et al.	Aug 2009	A1
20090216100	Ebner et al.	Aug 2009	A1
20090216103	Brister et al.	Aug 2009	A1
20090234200	Husheer	Sep 2009	A1
20090240120	Mensinger et al.	Sep 2009	A1
20090240128	Mensinger et al.	Sep 2009	A1
20090240193	Mensinger et al.	Sep 2009	A1
20090242399	Kamath et al.	Oct 2009	A1
20090242425	Kamath et al.	Oct 2009	A1
20090247855	Boock et al.	Oct 2009	A1
20090247856	Boock et al.	Oct 2009	A1
20090247931	Damgaard/Sorensen	Oct 2009	A1
20090253973	Bashan et al.	Oct 2009	A1
20090267765	Greene et al.	Oct 2009	A1
20090287073	Boock et al.	Nov 2009	A1
20090287074	Shults et al.	Nov 2009	A1
20090289796	Blumberg	Nov 2009	A1
20090298182	Schulat et al.	Dec 2009	A1
20090299155	Yang et al.	Dec 2009	A1
20090299156	Simpson et al.	Dec 2009	A1
20090299162	Brauker et al.	Dec 2009	A1
20090299276	Brauker et al.	Dec 2009	A1
20100010324	Brauker et al.	Jan 2010	A1
20100010331	Brauker et al.	Jan 2010	A1
20100010332	Brauker et al.	Jan 2010	A1
20100016687	Brauker et al.	Jan 2010	A1
20100016698	Rasdal et al.	Jan 2010	A1
20100022855	Brauker et al.	Jan 2010	A1
20100025238	Gottlieb et al.	Feb 2010	A1
20100030038	Brauker et al.	Feb 2010	A1
20100030053	Goode, Jr. et al.	Feb 2010	A1
20100030484	Brauker et al.	Feb 2010	A1
20100030485	Brauker et al.	Feb 2010	A1
20100036215	Goode, Jr. et al.	Feb 2010	A1
20100036216	Goode, Jr. et al.	Feb 2010	A1
20100036222	Goode, Jr. et al.	Feb 2010	A1
20100036223	Goode, Jr. et al.	Feb 2010	A1
20100036225	Goode, Jr. et al.	Feb 2010	A1
20100041971	Goode, Jr. et al.	Feb 2010	A1
20100045465	Brauker et al.	Feb 2010	A1
20100049024	Saint et al.	Feb 2010	A1
20100057040	Hayter	Mar 2010	A1
20100057041	Hayter	Mar 2010	A1
20100057042	Hayter	Mar 2010	A1
20100057044	Hayter	Mar 2010	A1
20100057057	Hayter et al.	Mar 2010	A1
20100063373	Kamath et al.	Mar 2010	A1
20100076283	Simpson et al.	Mar 2010	A1
20100081906	Hayter et al.	Apr 2010	A1
20100081908	Dobbles et al.	Apr 2010	A1
20100081910	Brister et al.	Apr 2010	A1
20100087724	Brauker et al.	Apr 2010	A1
20100096259	Zhang et al.	Apr 2010	A1
20100099970	Shults et al.	Apr 2010	A1
20100099971	Shults et al.	Apr 2010	A1
20100113897	Brenneman et al.	May 2010	A1
20100119693	Tapsak et al.	May 2010	A1
20100119881	Patel et al.	May 2010	A1
20100121169	Petisce et al.	May 2010	A1
20100152548	Koski	Jun 2010	A1
20100152554	Steine et al.	Jun 2010	A1
20100160757	Weinert et al.	Jun 2010	A1
20100160759	Celentano et al.	Jun 2010	A1
20100168538	Keenan et al.	Jul 2010	A1
20100190435	Cook et al.	Jul 2010	A1
20100191087	Talbot et al.	Jul 2010	A1
20100198142	Sloan et al.	Aug 2010	A1
20100213080	Celentano et al.	Aug 2010	A1
20100228111	Friman et al.	Sep 2010	A1
20100230285	Hoss et al.	Sep 2010	A1
20100235439	Goodnow et al.	Sep 2010	A1
20100259543	Tarassenko et al.	Oct 2010	A1
20100267161	Wu et al.	Oct 2010	A1
20100312176	Lauer et al.	Dec 2010	A1
20100313105	Nekoomaram et al.	Dec 2010	A1
20100324392	Yee et al.	Dec 2010	A1
20100324403	Brister et al.	Dec 2010	A1
20100325868	Wang et al.	Dec 2010	A1
20100326842	Mazza et al.	Dec 2010	A1
20100331651	Groll	Dec 2010	A1
20110004085	Mensinger et al.	Jan 2011	A1
20110004276	Blair et al.	Jan 2011	A1
20110021889	Hoss et al.	Jan 2011	A1
20110022411	Hjelm et al.	Jan 2011	A1
20110077469	Blocker et al.	Mar 2011	A1
20110097090	Cao	Apr 2011	A1
20110123971	Berkowitz et al.	May 2011	A1
20110125040	Crawford et al.	May 2011	A1
20110137571	Power et al.	Jun 2011	A1
20110148905	Simmons et al.	Jun 2011	A1
20110152637	Kateraas et al.	Jun 2011	A1
20110184482	Eberman et al.	Jul 2011	A1
20110184752	Ray et al.	Jul 2011	A1
20110208027	Wagner et al.	Aug 2011	A1
20110213225	Bernstein et al.	Sep 2011	A1
20110230741	Liang et al.	Sep 2011	A1
20110257895	Brauker et al.	Oct 2011	A1
20110263959	Young et al.	Oct 2011	A1
20110264378	Breton et al.	Oct 2011	A1
20110287528	Fern et al.	Nov 2011	A1
20110288574	Curry et al.	Nov 2011	A1
20110319729	Donnay et al.	Dec 2011	A1
20120010642	Lee et al.	Jan 2012	A1
20130111248	Ghesquiere et al.	May 2013	A1
20150326072	Petras et al.	Nov 2015	A1

Foreign Referenced Citations (155)

Number	Date	Country
2003259741	Feb 2004	AU
2468577	Jun 2003	CA
2495648	Feb 2004	CA
2143172	Jul 2005	CA
2498682	Sep 2005	CA
2555749	Sep 2005	CA
2632709	Jun 2007	CA
2396613	Mar 2008	CA
2678336	May 2008	CA
2615575	Jun 2008	CA
2626349	Sep 2008	CA
2701374	Apr 2009	CA
2413148	Aug 2010	CA
2728831	Jul 2011	CA
2617965	Oct 2011	CA
4401400	Jul 1995	DE
0098592	Jan 1984	EP
0127958	Dec 1984	EP
0320109	Jun 1989	EP
0353328	Feb 1990	EP
0390390	Oct 1990	EP
0396788	Nov 1990	EP
0286118	Jan 1995	EP
0680727	Nov 1995	EP
0724859	Aug 1996	EP
0805574	Nov 1997	EP
0973289	Jan 2000	EP
0678308	May 2000	EP
1048264	Nov 2000	EP
1292218	Mar 2003	EP
1077634	Jul 2003	EP
1568309	Aug 2005	EP
1666091	Jun 2006	EP
1703697	Sep 2006	EP
1704893	Sep 2006	EP
1956371	Aug 2008	EP
2031534	Mar 2009	EP
1897487	Nov 2009	EP
1897492	Nov 2009	EP
2113864	Nov 2009	EP
1897488	Dec 2009	EP
1681992	Apr 2010	EP
1448489	Aug 2010	EP
1971396	Aug 2010	EP
1725163	Dec 2010	EP
2260757	Dec 2010	EP
2201969	Mar 2011	EP
1413245	Jun 2011	EP
2153382	Feb 2012	EP
2284773	Feb 2012	EP
2409951	Jul 2005	GB
07311196	Nov 1995	JP
10305016	Nov 1998	JP
11056823	Mar 1999	JP
2000060803	Feb 2000	JP
2000354591	Dec 2000	JP
2001353159	Dec 2001	JP
2002513602	May 2002	JP
2003108677	Apr 2003	JP
2003144417	May 2003	JP
2003215122	Jul 2003	JP
2003520091	Jul 2003	JP
2004147705	May 2004	JP
2005218492	Aug 2005	JP
2006021031	Jan 2006	JP
2006048404	Feb 2006	JP
2006055530	Mar 2006	JP
2006280464	Oct 2006	JP
2006288619	Oct 2006	JP
2006289081	Oct 2006	JP
2007144141	Jun 2007	JP
2007152037	Jun 2007	JP
WO 1995028878	Feb 1995	WO
WO 1996025089	Aug 1996	WO
WO1996035370	Nov 1996	WO
WO 1997033513	Sep 1997	WO
WO 1998004902	Feb 1998	WO
WO 1998035053	Aug 1998	WO
WO 199927849	Jun 1999	WO
WO 199928736	Jun 1999	WO
WO 1999056613	Nov 1999	WO
WO 2000049940	Aug 2000	WO
WO 2000059370	Oct 2000	WO
WO 2000060350	Oct 2000	WO
WO 2000074753	Dec 2000	WO
WO 2000078992	Dec 2000	WO
WO 2001052935	Jul 2001	WO
WO 2001054753	Aug 2001	WO
WO 2002016905	Feb 2002	WO
WO 2002058537	Aug 2002	WO
WO 2003057027	Jul 2003	WO
WO 2003076893	Sep 2003	WO
WO 2003082091	Oct 2003	WO
WO 2003085372	Oct 2003	WO
WO 2004015539	Feb 2004	WO
WO 2004047445	Jun 2004	WO
WO 2004061420	Jul 2004	WO
WO 2004090503	Oct 2004	WO
WO 2004098405	Nov 2004	WO
WO 2005041766	May 2005	WO
WO 2005045744	May 2005	WO
WO 2005057175	Jun 2005	WO
WO 2005065538	Jul 2005	WO
WO 2005089103	Sep 2005	WO
WO 2005121785	Dec 2005	WO
WO 2006017358	Feb 2006	WO
WO 2006020212	Feb 2006	WO
WO 2006024671	Mar 2006	WO
WO 2006026741	Mar 2006	WO
WO 2006032653	Mar 2006	WO
WO 2006064397	Jun 2006	WO
WO 2006072035	Jul 2006	WO
WO 2006079114	Jul 2006	WO
WO 2006086423	Aug 2006	WO
WO 2006118947	Nov 2006	WO
WO 2006124099	Nov 2006	WO
WO 2007007459	Jan 2007	WO
WO 2007016399	Feb 2007	WO
WO 2007019289	Feb 2007	WO
WO 2007027788	Mar 2007	WO
WO 2007041069	Apr 2007	WO
WO 2007041070	Apr 2007	WO
WO 2007041248	Apr 2007	WO
WO 2007056638	May 2007	WO
WO 2007065285	Jun 2007	WO
WO 2007101223	Sep 2007	WO
WO 2007120363	Oct 2007	WO
WO 2007126444	Nov 2007	WO
WO 2007053832	Dec 2007	WO
WO 2007143225	Dec 2007	WO
WO 2007149319	Dec 2007	WO
WO 2008001366	Jan 2008	WO
WO 2008021913	Feb 2008	WO
WO 2008042760	Apr 2008	WO
WO 2008048452	Apr 2008	WO
WO 2008052374	May 2008	WO
WO 2008062099	May 2008	WO
WO 2008086541	Jul 2008	WO
WO 2008115409	Sep 2008	WO
WO 2008128210	Oct 2008	WO
WO 2008130896	Oct 2008	WO
WO 2008130897	Oct 2008	WO
WO 2008130898	Oct 2008	WO
WO 2008143943	Nov 2008	WO
WO 2008144445	Nov 2008	WO
WO 2008153693	Dec 2008	WO
WO 2009018058	Feb 2009	WO
WO 2009086216	Jul 2009	WO
WO 2009096992	Aug 2009	WO
WO 2009097594	Aug 2009	WO
WO 2010062898	Jun 2010	WO
WO 2010077329	Jul 2010	WO
WO 2011000528	Jan 2011	WO
WO 2011022418	Feb 2011	WO
WO011104616	Sep 2011	WO

Non-Patent Literature Citations (172)

Entry
U.S. Appl. No. 17/019,122 (US 2021/0000396), filed Sep. 11, 2020 (Jan. 7, 2021).
U.S. Appl. No. 16/032,017 (US 2018/0325434), filed Jul. 10, 2018 (Nov. 15, 2018).
U.S. Appl. No. 14/094,719 (US 2014/0088382), filed Dec. 2, 2013 (Mar. 27, 2014).
U.S. Appl. No. 12/143,731 (US 2008/0319295), filed Jun. 20, 2008 (Dec. 25, 2008).
U.S. Appl. No. 17/019,122, Jan. 21, 2021 Non-Final Office Action.
U.S. Appl. No. 17/019,122, Dec. 18, 2020 Response to Restriction Requirement.
U.S. Appl. No. 17/019,122, Dec. 15, 2020 Restriction Requirement.
U.S. Appl. No. 16/032,017, Jan. 6, 2021 Non-Final Office Action.
U.S. Appl. No. 14/094,719, Feb. 6, 2020 Abandonment.
U.S. Appl. No. 14/094,719, Jul. 10, 2019 Final Office Action.
U.S. Appl. No. 14/094,719, Mar. 14, 2019 Response After Non-Final Office Action.
U.S. Appl. No. 14/094,719, Dec. 26, 2018 Non-Final Office Action.
U.S. Appl. No. 14/094,719, Nov. 28, 2018 Request for Continued Examination.
U.S. Appl. No. 14/094,719, Nov. 28, 2018 Response After Final Office Action.
U.S. Appl. No. 14/094,719, Aug. 28, 2018 Final Office Action.
U.S. Appl. No. 14/094,719, Jul. 24, 2018 Supplemental Response.
U.S. Appl. No. 14/094,719, Apr. 21, 2018 Response After Non-Final Office Action.
U.S. Appl. No. 14/094,719, Jan. 25, 2018 Non-Final Office Action.
U.S. Appl. No. 14/094,719, Sep. 27, 2017 Request for Continued Examination.
U.S. Appl. No. 14/094,719, Sep. 27, 2017 Response After Final Office Action.
U.S. Appl. No. 14/094,719, Mar. 31, 2017 Final Office Action.
U.S. Appl. No. 14/094,719, Dec. 28, 2016 Response After Non-Final Office Action.
U.S. Appl. No. 14/094,719, Sep. 28, 2016 Non-Final Office Action.
U.S. Appl. No. 14/094,719, Oct. 2, 2015 Preliminary Amendment.
U.S. Appl. No. 12/143,731, Oct. 31, 2013 Issue Fee Payment.
U.S. Appl. No. 12/143,731, Sep. 27, 2013 Notice of Allowance.
U.S. Appl. No. 12/143,731, Sep. 11, 2013 Response After Final Office Action.
U.S. Appl. No. 12/143,731, Jul. 17, 2013 Final Office Action.
U.S. Appl. No. 12/143,731, Jul. 12, 2013 Response After Non-Final Office Action.
U.S. Appl. No. 12/143,731, Oct. 18, 2012 Non-Final Office Action.
U.S. Appl. No. 12/143,731, Jul. 19, 2012 Response After Non-Final Office Action.
U.S. Appl. No. 12/143,731, Jul. 19, 2012 Non-Final Office Action.
U.S. Appl. No. 12/143,731, Jan. 17, 2012 Response After Non-Final Office Action.
U.S. Appl. No. 12/143,731, Oct. 17, 2011 Non-Final Office Action.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519/1526.
Australian Patent Application No. 2008265541, Examiner's Report dated Nov. 29, 2013.
Australian Patent Application No. 2008265541, Examiner's Report dated Oct. 15, 2012.
Australian Patent Application No. 2008265542, Examiner's Report dated Oct. 4, 2012.
Australian Patent Application No. 2013205279, Examiner's Report dated Aug. 8, 2014.
Australian Patent Application No. 2015275271, Examiner's Report dated Feb. 13, 2017.
Australian Patent Application No. 2017254903, Examiner's Report dated Dec. 11, 2018.
Australian Patent Application No. 2018200899, Examiner's Report dated Dec. 6, 2018.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25/33.
Blank, T. B., et al., “Clinical Results From a Non/Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1/10.
Brooks, S. L., et al., “Development of an on/Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45/56.
Canadian Patent Application No. 2,690,870, Examiner's Report dated Feb. 24, 2015.
Canadian Patent Application No. 2,690,742, Examiner's Report mailed Dec. 30, 2015.
Canadian Patent Application No. 2,690,870, Examiner's Report mailed Mar. 23, 2016.
Canadian Patent Application No. 2,690,742, Examiner's Report mailed Oct. 24, 2016.
Canadian Patent Application No. 2,690,742. Notice of Allowance dated Sep. 26, 2017.
Cass, A. E., et al., “Ferrocene/Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56 No. 4, 1984, 667/671.
Chinese Patent Application No. 200880021299.1, English Translation & Original Language of Office Action dated Aug. 15, 2011.
Chinese Patent Application No. 200880021299.1, English Translation & Original Language of Office Action dated Dec. 14, 2010.
Chinese Patent Application No. 200880021299.1, English Translation & Original Language of Office Action dated May 22, 2012.
Chinese Patent Application No. 201310161229.9, Original Language & English Translation of Office Action dated Jun. 3, 2014.
Chinese Patent Application No. 201310161229.9, Original Language & English Translation of Office Action dated Feb. 17, 2015.
Chinese Patent Application No. 201310161229.9, Original Language & English Translation of Office Action dated Jul. 30, 2015.
Chinese Patent Application No. 201310161229.9, Original Language & English Translation of Office Action dated Feb. 23, 2016.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240/1244.
Diem, P., et al., “Clinical Performance of a Continuous Viscometric Affinity Sensor for Glucose”, Diabetes Technology & Therapeutics, vol. 6, 2004, pp. 790/799.
El/Khatib, F. H, et al., “Adaptive Closed/Loop Control Provides Blood/Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine”, Journal of Diabetes, Science and Technology, vol. 1, No. 2, 2007, pp. 181/192.
European Patent Application No. 08745799.0, Extended European Search Report dated Oct. 16, 2012.
European Patent Application No. 08771681.7, Extended European Search Report dated Oct. 16, 2012.
European Patent Application No. 08771682.5, Extended European Search Report dated May 11, 2012.
European Patent Application No. 08771681.7, Examination Report dated Jun. 6, 2014.
European Patent Application No. 08771682.5, Examination Report dated Dec. 18, 2015.
European Patent Application No. 08771681.7, Examination Report dated Jun. 17, 2016.
European Patent Application No. 08771682.5, Examination Report dated Jun. 29, 2016.
European Patent Application No. 08771682.5, Examination Report dated Feb. 2, 2017.
European Patent Application No. 08771681.7, Examination Report dated May 10, 2017.
European Patent Application No. 08771682.5, Examination Report dated Aug. 2, 2017.
European Patent Application No. 10739031.2, Opposition filed Dec. 20, 2018.
European Patent Application No. 13000105.0, Opposition filed Jan. 4, 2019.
European Patent Application No. 18192278.2, Extended European Search Report dated Mar. 13, 2019.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology /Results from a 3/Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769/779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
Garg, S., et al., “Improvement in Glycemic Excursions with a Transcutaneous, Real/Time Continuous Glucose Sensor”, Diabetes Care, vol. 29, No. 1, 2006, pp. 44/50.
Hao, Y., “Topical Review; Wireless Body Sensor Networks for Health/Monitoring Applications”, Physiological Measurement, vol. 29, No. 11, Nov. 1, 2008, pp. R27/R56.
Indian Patent Application No. 8050/DELNP/2009, Examination Report dated Jun. 19, 2017.
Isermann, R., “Supervision, Fault/Detection and Fault/Diagnosis Methods / An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639/652.
Isermann, R., et al., “Trends in the Application of Model/Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709/719.
Japanese Patent Application No. 2010/513476, English Translation of Office Action dated Jul. 23, 2013.
Japanese Patent Application No. 2010/513477, Original Language & English Translation of Office Action dated May 13, 2014.
Japanese Patent Application No. 2010/513476, Original Language and English Translation of Office Action dated Jun. 24, 2014.
Japanese Patent Application No. 2014/187515, Original Language & English Translation of Office Action dated Aug. 18, 2015.
Japanese Patent Application No. 2014/187515, Original Language & English Translation of Office Action dated Jul. 5, 2016.
Japanese Patent Application No. 2016/217028, Original Language & English Translation of Office Action dated Sep. 5, 2017.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303/1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Kondepati, V., et al., “Recent Progress in Analytical Instrumentation for Glycemic Control in Diabetic and Critically Ill Patients”, Analytical Bioanalytical Chemistry, vol. 388, 2007, pp. 545/ 563.
Lo, B., et al., “Key Technical Challenges and Current Implementations of Body Sensor Networks”, Body Sensor Networks, 2005, pp. 1/5.
Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573/587.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short/Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72/74.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near/Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651/1658.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off/Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367/376.
McKean, B. D., et al., “A Telemetry/Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526/532.
PCT Application No. PCT/US2008/067792, International Preliminary Report on Patentability dated Jan. 7, 2010.
PCT Application No. PCT/US2008/067792, International Search Report and Written Opinion of the International Searching Authority dated Sep. 30, 2008.
PCT Application No. PCT/US2008/067793, International Preliminary Report on Patentability dated Jan. 7, 2010.
PCT Application No. PCT/US2008/067793, International Search Report and Written Opinion of the International Searching Authority dated Sep. 8, 2008.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335/346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213/217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268/2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3/mm Amperometric Microsensors”, The American Physiological Society, 1995, E155/ E161.
Rodriguez, N., et al., “Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces”, IEEE Transactions on Biomedical Circuits and Systems, IEEE, vol. 1 No. 1, 2007, pp. 19/27.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199/241.
Sakakida, M., et al., “Development of Ferrocene/Mediated Needle/Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145/158.
Sakakida, M., et al., “Ferrocene/Mediated Needle/Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13/14, 1993, pp. 319/322.
Salditt, P., “Trends in Medical Device Design and Manufacturing”, SMTA News and Journal of Surface Mount Technology, vol. 17, 2004, pp. 19/24.
Salehi, C., et al., “A Telemetry/Instrumentation System for Long/Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289/2308.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294/299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401/406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179/184.
Shichiri, M., et al., “In Vivo Characteristics of Needle/Type Glucose Sensor / Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17/20.
Shichiri, M., et al., “Membrane Design for Extending the Long/Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309/313.
Shichiri, M., et al., “Needle/type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed/Loop Prosthetic Systems, Chapter 15, 1985, pp. 197/210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle/Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298/301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle/Type Glucose Sensor”, The Lancet, 1982, pp. 1129/1131.
Shults, M. C., et al., “A Telemetry/Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937/942.
Sternberg, R., et al., “Study and Development of Multilayer Needle/Type Enzyme/Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27/40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255/261.
Tung, S., “Layers of Security for Active RFID Tags”, RFID Handbook: Applications, Technology, Security, and Privacy, Edited by Ehson, et al., Chapter 33, 2008, pp. 1/28.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85/115.
Updike, S. J., et al., “Principles of Long/Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Bod : Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117/137.
U.S. Appl. No. 12/143,734, Advisory Action dated Oct. 11, 2012.
U.S. Appl. No. 12/143,734, Office Action dated Jan. 23, 2013.
U.S. Appl. No. 12/143,734, Office Action dated Jan. 27, 2012.
U.S. Appl. No. 12/143,734, Office Action dated Jul. 25, 2012.
U.S. Appl. No. 12/143,734, Office Action dated Oct. 14, 2011.
U.S. Appl. No. 12/625,510, Office Action dated Mar. 15, 2013.
U.S. Appl. No. 12/625,510, Office Action dated May 23, 2012.
U.S. Appl. No. 12/625,510, Office Action dated Aug. 20, 2012.
U.S. Appl. No. 12/625,510, Office Action dated Dec. 1, 2011.
U.S. Appl. No. 12/628,173, Advisory Action dated Sep. 17, 2012.
U.S. Appl. No. 12/628,173, Office Action dated Jan. 16, 2014.
U.S. Appl. No. 12/628,173, Office Action dated Jun. 11, 2012.
U.S. Appl. No. 12/628,173, Office Action dated Jun. 21, 2013.
U.S. Appl. No. 12/628,173, Office Action dated Nov. 8, 2011.
U.S. Appl. No. 12/628,177, Office Action dated Aug. 20, 2012.
U.S. Appl. No. 12/628,177, Office Action dated Mar. 18, 2013.
U.S. Appl. No. 12/628,177, Office Action dated Mar. 29, 2012.
U.S. Appl. No. 12/628,177, Office Action dated Nov. 9, 2011.
U.S. Appl. No. 12/628,198, Office Action dated Mar. 19, 2013.
U.S. Appl. No. 12/628,198, Office Action dated Aug. 20, 2012.
U.S. Appl. No. 12/628,198, Office Action dated Mar. 29, 2012.
U.S. Appl. No. 12/628,198, Office Action dated Nov. 8, 2011.
U.S. Appl. No. 12/628,201, Office Action dated Aug. 20, 2012.
U.S. Appl. No. 12/628,201, Office Action dated Mar. 14, 2013.
U.S. Appl. No. 12/628,201, Office Action dated Mar. 28, 2012.
U.S. Appl. No. 12/628,201, Office Action dated Nov. 10, 2011.
U.S. Appl. No. 12/628,203, Office Action dated Aug. 21, 2012.
U.S. Appl. No. 12/628,203, Office Action dated Mar. 14, 2013.
U.S. Appl. No. 12/628,203, Office Action dated Mar. 28, 2012.
U.S. Appl. No. 12/628,203, Office Action dated Nov. 10, 2011.
U.S. Appl. No. 12/628,210, Office Action dated Aug. 21, 2012.
U.S. Appl. No. 12/628,210, Office Action dated Mar. 20, 2013.
U.S. Appl. No. 12/628,210, Office Action dated Mar. 28, 2012.
U.S. Appl. No. 12/628,210, Office Action dated Nov. 14, 2011.
U.S. Appl. No. 13/730,696, Office Action dated Jul. 6, 2015.
U.S. Appl. No. 14/133,635, Office Action dated Feb. 11, 2016.
U.S. Appl. No. 14/133,635, Office Action dated Jul. 26, 2016.
U.S. Appl. No. 14/133,635, Office Action dated Nov. 16, 2016.
U.S. Appl. No. 14/133,635, Office Action dated Mar. 7, 2017.
U.S. Appl. No. 14/133,635, Advisory Action dated Jul. 6, 2017.
U.S. Appl. No. 14/133,635, Office Action dated Aug. 25, 2017.
U.S. Appl. No. 15/985,615, Office Action dated Jul. 27, 2018.
U.S. Appl. No. 15/985,615, Office Action dated Mar. 7, 2019.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957/964.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613/1617.

Related Publications (1)

	Number	Date	Country
	20210151182 A1	May 2021	US

Provisional Applications (1)

	Number	Date	Country
	60945579	Jun 2007	US

Continuations (4)

	Number	Date	Country
Parent	17019122	Sep 2020	US
Child	17157611		US
Parent	16032017	Jul 2018	US
Child	17019122		US
Parent	14094719	Dec 2013	US
Child	16032017		US
Parent	12143731	Jun 2008	US
Child	14094719		US

Health management devices and methods

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Abstract